AstraZeneca (AZN) 6-K28 Jul 232023 Q2 Current report (foreign)Financial data

Company Profile

Document and Entity Information

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2023
Document and Entity Information
Entity Registrant Name	AstraZeneca PLC
Entity Central Index Key	0000901832
Document Type	6-K
Document Period End Date	Jun. 30, 2023
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023

Condensed consolidated statemen

Condensed consolidated statement of comprehensive income - USD ($) shares in Millions, $ in Millions		3 Months Ended			6 Months Ended
		Jun. 30, 2023	[2]	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Condensed consolidated statement of comprehensive income
Total Revenue	[1]	$ 11,416		$ 10,771	$ 22,295	$ 22,161
Product Sales		10,882		10,630	21,448	21,610
Alliance revenue		341		138	627	290
Collaboration Revenue		193		3	220	261
Cost of sales		(1,960)		(2,998)	(3,865)	(6,509)
Gross profit		9,456		7,773	18,430	15,652
Distribution expense		(131)		(129)	(265)	(254)
Research and development expense		(2,667)		(2,546)	(5,278)	(4,679)
Selling, general and administrative expense		(4,986)		(4,681)	(9,045)	(9,521)
Other operating income and expense		784		122	1,163	219
Operating profit		2,456		539	5,005	1,417
Finance income		64		18	141	35
Finance expense		(431)		(311)	(795)	(647)
Share of after tax (losses)/profits in associates and joint ventures		(1)		1	(1)	(5)
Profit before tax		2,088		247	4,350	800
Taxation		(268)		113	(726)	(52)
Profit for the period		1,820		360	3,624	748
Other comprehensive income
Remeasurement of the defined benefit pension liability		17		696	7	1,031
Net gains on equity investments measured at fair value through other comprehensive income		(94)		(30)	(48)	(12)
Fair value movements related to own credit risk on bonds designated as fair value through profit or loss		2		2	4	2
Tax on items that will not be reclassified to profit or loss		(29)		(181)	(5)	(275)
Total other comprehensive income that will not be reclassified to profit or loss, net of tax		(104)		487	(42)	746
Foreign exchange arising on consolidation		(209)		(1,107)	105	(1,326)
Foreign exchange arising on designated liabilities in net investment hedges		(94)		(163)	(101)	(195)
Fair value movements on cash flow hedges		33		(143)	89	(138)
Fair value movements on cash flow hedges transferred to profit and loss		4		120	(71)	131
Fair value movements on derivatives designated in net investment hedges		24		42	40	34
Costs of hedging		(1)		(13)	(1)	(13)
Tax on items that may be reclassified subsequently to profit or loss				45	12	46
Other comprehensive income that may be subsequently to profit or loss, net of tax		(243)		(1,219)	73	(1,461)
Other comprehensive income/(loss), net of tax		(347)		(732)	31	(715)
Total comprehensive income/(loss) for the period		1,473		(372)	3,655	33
Profit attributable to:
Owners of the Parent		1,818		360	3,621	746
Non-controlling interests		2			3	2
Profit for the period		1,820		360	3,624	748
Total comprehensive income/(loss) attributable to:
Owners of the Parent		1,471		(372)	3,652	33
Non-controlling interests		2			3
Total comprehensive income/(loss) for the period		$ 1,473		$ (372)	$ 3,655	$ 33
Basic earnings per $0.25 Ordinary Share		$ 1.17		$ 0.23	$ 2.34	$ 0.48
Diluted earnings per $0.25 Ordinary Share		$ 1.17		$ 0.23	$ 2.32	$ 0.48
Weighted average number of Ordinary Shares in issue (m)		1,550		1,549	1,549	1,548
Diluted weighted average number of Ordinary Shares in issue (m)		1,560		1,560	1,560	1,561

[1] Effective 1 January 2023, the Group has updated the presentation of Total Revenue. See Note 1 for further details of the presentation of Alliance Revenue. The Q2 2023 and Q2 2022 information in respect of the three months ended 30 June 2023 and 30 June 2022 respectively included in the Interim Financial Statements have not been reviewed by PricewaterhouseCoopers LLP.

Condensed consolidated statem_2

Condensed consolidated statement of comprehensive income (Parenthetical) - $ / shares	Jun. 30, 2023	Jun. 30, 2022
Condensed consolidated statement of comprehensive income
Par value per ordinary share	$ 0.25	$ 0.25

Condensed consolidated statem_3

Condensed consolidated statement of financial position - USD ($) $ in Millions	Jun. 30, 2023	[1]	Dec. 31, 2022	Jun. 30, 2022
Non-current assets
Property, plant and equipment	$ 8,675		$ 8,507	$ 8,722
Right-of-use assets	949		942	905
Goodwill	19,960		19,820	19,821
Intangible assets	38,326		39,307	39,900
Investments in associates and joint ventures	72		76	56
Other investments	1,071		1,066	1,124
Derivative financial instruments	163		74	113
Other receivables	752		835	881
Deferred tax assets	3,736		3,263	4,140
Total non-current assets	73,704		73,890	75,662
Current assets
Inventories	5,051		4,699	6,220
Trade and other receivables	11,092		10,521	8,908
Other investments	148		239	70
Derivative financial instruments	44		87	109
Intangible assets				89
Income tax receivable	840		731	704
Cash and cash equivalents	5,664		6,166	4,817
Assets held for sale			150
Total current assets	22,839		22,593	20,917
Total assets	96,543		96,483	96,579
Current liabilities
Interest-bearing loans and borrowings	(4,556)		(5,314)	(2,162)
Lease liabilities	(231)		(228)	(220)
Trade and other payables	(19,738)		(19,040)	(17,821)
Derivative financial instruments	(83)		(93)	(90)
Provisions	(567)		(722)	(541)
Income tax payable	(1,200)		(896)	(981)
Total current liabilities	(26,375)		(26,293)	(21,815)
Non-current liabilities
Interest-bearing loans and borrowings	(24,329)		(22,965)	(26,461)
Lease liabilities	(722)		(725)	(685)
Derivative financial instruments	(68)		(164)	(180)
Deferred tax liabilities	(2,800)		(2,944)	(5,275)
Retirement benefit obligations	(1,078)		(1,168)	(1,310)
Provisions	(1,357)		(896)	(892)
Other payables	(2,398)		(4,270)	(4,010)
Total non-current liabilities	(32,752)		(33,132)	(38,813)
Total liabilities	(59,127)		(59,425)	(60,628)
Net assets	37,416		37,058	35,951
Equity
Share capital	387		387	387
Share premium account	35,163		35,155	35,134
Other reserves	2,076		2,069	2,068
Retained earnings	(234)		(574)	(1,657)
Total equity attributable to owners of parent	37,392		37,037	35,932
Non-controlling interests	24		21	19
Total equity	$ 37,416		$ 37,058	$ 35,951

[1] The Condensed consolidated statement of financial position as at 30 June 2023 and 30 June 2022 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2022 has been audited by PricewaterhouseCoopers LLP.

Condensed consolidated statem_4

Condensed consolidated statement of changes in equity - USD ($) $ in Millions	Share Capital	Share Premium account	Other reserves	Retained earnings	Total attributable to owners of the parent	Non-controlling interests.	Total
Equity at beginning of period at Dec. 31, 2021	$ 387	$ 35,126	$ 2,045	$ 1,710	$ 39,268	$ 19	$ 39,287
Profit for the period				746	746	2	748
Other comprehensive income (loss)				(713)	(713)	(2)	(715)
Transfer to other reserves			23	(23)
Dividends				(3,046)	(3,046)		(3,046)
Issue of Ordinary Shares		8			8		8
Share-based payments charge for the period				346	346		346
Settlement of share plan awards				(677)	(677)		(677)
Net movement		8	23	(3,367)	(3,336)		(3,336)
Equity at end of period at Jun. 30, 2022	387	35,134	2,068	(1,657)	35,932	19	35,951
Equity at beginning of period at Dec. 31, 2022	387	35,155	2,069	(574)	37,037	21	37,058
Profit for the period				3,621	3,621	3	3,624
Other comprehensive income (loss)				31	31		31
Transfer to other reserves			7	(7)
Dividends				(3,047)	(3,047)		(3,047)
Issue of Ordinary Shares		8			8		8
Share-based payments charge for the period				274	274		274
Settlement of share plan awards				(532)	(532)		(532)
Net movement		8	7	340	355	3	358
Equity at end of period at Jun. 30, 2023	$ 387	$ 35,163	$ 2,076	$ (234)	$ 37,392	$ 24	$ 37,416	[1]

[1] The Condensed consolidated statement of financial position as at 30 June 2023 and 30 June 2022 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2022 has been audited by PricewaterhouseCoopers LLP.

Condensed consolidated statem_5

Condensed consolidated statement of cash flows - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023		Jun. 30, 2022
Cash flows from operating activities
Profit before tax	$ 4,350		$ 800
Finance income and expense	654		612
Share of after tax losses of associates and joint ventures	1		5
Depreciation, amortisation and impairment	2,778		2,666
(Increase)/decrease in working capital and short-term provisions	(747)		2,391
Gains on disposal of intangible assets	(249)		(81)
Fair value movements on contingent consideration arising from business combinations	202		293
Non-cash and other movements	(594)		(814)
Cash generated from operations	6,395		5,872
Interest paid	(483)		(386)
Tax paid	(1,061)		(1,006)
Net cash inflow from operating activities	4,851		4,480
Cash flows from investing activities
Acquisition of subsidiaries, net of cash acquired	(189)
Payments upon vesting of employee share awards attributable to business combinations	(23)		(158)
Payment of contingent consideration from business combinations	(398)		(367)
Purchase of property, plant and equipment	(517)		(472)
Disposal of property, plant and equipment	126
Purchase of intangible assets	(1,436)		(434)
Disposal of intangible assets	288		442
Movement in profit-participation liability	175
Purchase of non-current asset investments	(26)		(28)
Disposal of non-current asset investments	10		35
Movement in short-term investments, fixed deposits and other investing instruments	90		9
Payments to associates and joint ventures			(5)
Interest received	134		10
Net cash outflow from investing activities	(1,766)		(968)
Net cash inflow before financing activities	3,085		3,512
Cash flows from financing activities
Proceeds from issue of share capital	8		8
Issue of loans and borrowings	3,816
Repayment of loans and borrowings	(3,408)		(1,257)
Dividends paid	(3,069)		(2,971)
Hedge contracts relating to dividend payments	27		(77)
Repayment of obligations under leases	(129)		(134)
Movement in short-term borrowings	72		316
Payment of Acerta Pharma share purchase liability	(867)		(920)
Net cash outflow from financing activities	(3,550)		(5,035)
Net decrease in Cash and cash equivalents in the period	(465)		(1,523)
Cash and cash equivalents at the beginning of the period	5,983		6,038
Exchange rate effects	(47)		(35)
Cash and cash equivalents at the end of the period	5,471		4,480
Cash and cash equivalents	5,664	[1]	4,817
Overdrafts	$ (193)		$ (337)

[1] The Condensed consolidated statement of financial position as at 30 June 2023 and 30 June 2022 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2022 has been audited by PricewaterhouseCoopers LLP.

Basis of preparation and accoun

Basis of preparation and accounting policies	6 Months Ended
Basis of preparation and accounting policies	Jun. 30, 2023
Basis of preparation and accounting policies
Basis of preparation and accounting policies	Notes to the Interim Financial Statements Note 1: Basis of preparation and accounting policies These unaudited condensed consolidated Interim Financial Statements for the six months ended 30 June 2023 have been prepared in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’ (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union, UK-adopted IAS 34 and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority and with the requirements of the Companies Act 2006 as applicable to companies reporting under those standards. The unaudited Interim Financial Statements for the six months ended 30 June 2023 were approved by the Board of Directors for publication on 28 July 2023. This results announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The annual financial statements of the Group for the year ended 31 December 2022 were prepared in accordance with UK-adopted International Accounting Standards and with the requirements of the Companies Act 2006. The annual financial statements also comply fully with IFRSs as issued by the IASB and International Accounting Standards as adopted by the European Union. Except for the estimation of the interim income tax charge, the Interim Financial Statements have been prepared applying the accounting policies that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2022. The comparative figures for the financial year ended 31 December 2022 are not the Group’s statutory accounts for that financial year. Those accounts have been reported on by the Group’s auditors and have been delivered to the registrar of companies; their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006. Alliance and Collaboration Revenues Effective 1 January 2023, the Group has updated the presentation of Total Revenue on the face of the Statement of Comprehensive Income to include Alliance Revenue as a separate element to Collaboration Revenue. Alliance Revenue, previously reported within Collaboration Revenue, comprises income related to sales made by collaboration partners, where AstraZeneca is entitled to a profit share, revenue share or royalties, which are recurring in nature while the collaboration arrangement remains in place. Alliance Revenue does not include Product Sales where AstraZeneca is leading commercialisation in a territory. Collaboration Revenue arising from collaborative arrangements where the Group retains a significant ongoing economic interest and receives upfront amounts and event-triggered milestones, which arise from the licensing of intellectual property, will continue to be reported as Collaboration Revenue. In collaboration arrangements either AstraZeneca or the collaborator acts as principal in sales to the end customer. Where AstraZeneca acts as principal, we record 100% of sales to the end customer within Product Sales. The revised presentation reflects the increasing importance of income arising from profit share arrangements where collaboration partners are responsible for booking revenues in some or all territories. The comparative revenue reported in H1 2023 relating to the half year to 30 June 2022 has been retrospectively adjusted to reflect the new split of Total Revenue, resulting in Alliance Revenue being reported for the half year 30 June 2022 of $290m, however the combined total of Alliance Revenue and Collaboration Revenue is equal to the previously reported Collaboration Revenue total for the half year 30 June 2022. Going concern The Group has considerable financial resources available. As at 30 June 2023, the Group has $12.6bn in financial resources (Cash and cash equivalent balances of $5.7bn and undrawn committed bank facilities of $6.9bn available, of which $2.0bn of the facilities are available until February 2025 and the other $4.9bn are available until April 2026, with $4.6bn of borrowings due within one year). These facilities contain no financial covenants and were undrawn at 30 June 2023. The Group’s revenues are largely derived from sales of medicines covered by patents which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in some of our significant markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. Accordingly, they continue to adopt the going concern basis in preparing the Interim Financial Statements. Legal proceedings The information contained in Note 6 updates the disclosures concerning legal proceedings and contingent liabilities in the Group’s Annual Report and Form 20-F Information 202 2. IAS 12 ‘Income Taxes’ On 25 May 2023, the IASB issued an amendment to IAS 12 ‘Income Taxes’ to clarify how the effects of the global minimum tax framework should be accounted for and disclosed effective 1 January 2023. This was endorsed by the UK Endorsement Board on 19 July 2023 and has been adopted by the Company for 2023 reporting. The Company has applied the exemption to recognising and disclosing information about deferred tax assets and liabilities related to Pillar 2 income taxes. The Company is currently assessing the potential impact of these draft rules upon its financial statements.

Intangible assets

Intangible assets	6 Months Ended
Intangible assets	Jun. 30, 2023
Intangible assets
Intangible assets	Note 2: Intangible assets In accordance with IAS 36 ‘Impairment of Assets’, reviews for triggers of impairment or impairment reversals at an individual asset or cash generating unit level were conducted, and impairment tests carried out where triggers were identified. As a result, total impairment charges of $320m have been recorded against intangible assets during the six months ended 30 June 2023 (H1 2022: $26m net reversal). Net impairment charges in respect of medicines in development were $320m (H1 2022: $9m reversal) including the $244m impairment of the ALXN1840 intangible asset, following decision to discontinue this development programme in Wilson’s disease. As previously disclosed, on 16 January 2023 AstraZeneca completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts). The purchase price allocation exercise has completed, with the fair value of total consideration determined at $267m. Intangible assets of $100m and goodwill of $158m were recognised in the acquisition balance sheet, as well as a cash outflow of $189m net of cash acquired. Future contingent milestones-based and non-contingent consideration is payable to a maximum of $120m. Neogene’s results have been consolidated into the Group’s results from 16 January 2023. The acquisition of CinCor completed on 24 February 2023, recorded as an asset acquisition, with consideration and net assets acquired of $1,268m, which included intangible assets acquired of $780m, $424m of cash and cash equivalents, and $75m of marketable securities. The Condensed consolidated statement of cash flows includes a $1,204m payment for the intangible assets which is presented net of the $424m cash and cash equivalents acquired within Purchase of intangible assets, whilst the $75m increase in marketable securities is presented within Movement in short-term investments, fixed deposits and other investing instruments. Contingent consideration of up to $496m could be paid on achievement of regulatory milestones, and will be recognised when the associated milestones are triggered.

Net Debt

Net Debt	6 Months Ended
Net Debt	Jun. 30, 2023
Net Debt.
Net Debt	Note 3: Net debt The table below provides an analysis of Net Debt and a reconciliation of Net Cash Flow to the movement in Net Debt. The Group monitors Net Debt as part of its capital-management policy as described in Note 28 of the Annual Report and Form 20-F Information 2022 Table 25: Net debt At 1 Jan Cash Non-cash Exchange At 30 Jun 2023 flow Acquisitions & other movements 2023 $m $m $m $m $m $m Non-current instalments of loans (22,965) (3,827) - 2,587 (124) (24,329) Non-current instalments of leases (725) (1) (6) 10 - (722) Total long-term debt (23,690) (3,828) (6) 2,597 (124) (25,051) Current instalments of loans (4,964) 3,409 - (2,594) 14 (4,135) Current instalments of leases (228) 141 (2) (146) 4 (231) Bank collateral received (89) (61) - - - (150) Other short-term borrowings excluding overdrafts (78) (11) - - 11 (78) Overdrafts (183) (10) - - - (193) Total current debt (5,542) 3,468 (2) (2,740) 29 (4,787) Gross borrowings (29,232) (360) (8) (143) (95) (29,838) Net derivative financial instruments (96) (27) - 179 - 56 Net borrowings (29,328) (387) (8) 36 (95) (29,782) Cash and cash equivalents 6,166 (455) - - (47) 5,664 Other investments - current 239 (90) - - (1) 148 Cash and investments 6,405 (545) - - (48) 5,812 Net debt (22,923) (932) (8) 36 (143) (23,970) Non-cash movements in the period include fair value adjustments under IFRS 9 Financial Instruments. The Group has agreements with some bank counterparties whereby the parties agree to post cash collateral on financial derivatives, for the benefit of the other, equivalent to the market valuation of the derivative positions above a predetermined threshold. The carrying value of such cash collateral held by the Group at 30 June 2023 was $150m (31 December 2022: $89m) and the carrying value of such cash collateral posted by the Group at 30 June 2023 was $136m (31 December 2022: $162m). The equivalent GAAP measure to Net debt is ‘liabilities arising from financing activities’, which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives shown above and includes the Acerta Pharma share purchase liability of $805m (31 December 2022: $1,646m), which is shown in current other payables. Net debt increased by $1,047m in the half to $23,970m. Details of the committed undrawn bank facilities are disclosed within the going concern section of Note 1. During the six months ended 30 June 2023, there were no changes to the Company’s solicited credit ratings issued by Standard and Poor’s (long term: A; short term: A-1) and from Moody’s (long term: A3; short term: P-2)

Financial instruments

Financial instruments	6 Months Ended
Financial instruments	Jun. 30, 2023
Financial instruments
Financial instruments	Note 4: Financial Instruments As detailed in the Group’s most recent annual financial statements, the principal financial instruments consist of derivative financial instruments, other investments, trade and other receivables, cash and cash equivalents, trade and other payables, lease liabilities and interest-bearing loans and borrowings. The Group has certain equity investments that are categorised as Level 3 in the fair value hierarchy that are held at $247m at 30 June 2023 (31 December 2022: $186m) and for which fair value gains of $1m have been recognised in the six months ended 30 June 2023 (H1 2022: $48m). In the absence of specific market data, these unlisted investments are held at fair value based on the cost of investment and adjusting as necessary for impairments and revaluations on new funding rounds, which are seen to approximate the fair value. All other fair value gains and/or losses that are presented in Net losses on equity investments measured at fair value through other comprehensive income in the Condensed consolidated statement of comprehensive income for the six months ended 30 June 2023 are Level 1 fair value measurements, valued based on quoted prices in active markets. Financial instruments measured at fair value include $1,083m of other investments, $4,400m held in money-market funds, $289m of loans designated at fair value through profit or loss and $56m of derivatives as at 30 June 2023. With the exception of derivatives being Level 2 fair valued, certain equity investments as described above and an equity warrant of $16m categorised as Level 3, the aforementioned balances are Level 1 fair valued. Financial instruments measured at amortised cost include $136m of cash collateral pledged to counterparties. The total fair value of interest-bearing loans and borrowings at 30 June 2023, which have a carrying value of $29,838m in the Condensed consolidated statement of financial position, was $28,591m. As announced in April 2023, the contractual relationship between AstraZeneca and Swedish Orphan Biovitrum AB (Sobi) relating to future sales of Beyfortus Table 26: Financial instruments – contingent consideration 2023 2022 Diabetes alliance Other Total Total $m $m $m $m At 1 January 2,124 98 2,222 2,865 Additions through business combinations - 60 60 - Settlements (395) (3) (398) (367) Disposals - - - (121) Revaluations 229 (27) 202 293 Discount unwind 62 4 66 85 At 30 June 2,020 132 2,152 2,755 Contingent consideration arising from business combinations is fair valued using decision-tree analysis, with key inputs including the probability of success, consideration of potential delays and the expected levels of future revenues. The contingent consideration balance relating to BMS’s share of the global diabetes alliance of $2,020m (31 December 2022: $2,124m) would increase/decrease by $202m with an increase/decrease in sales of 10%, as compared with the current estimates.

Pensions and other post-retirem

Pensions and other post-retirement benefit obligations	6 Months Ended
Pensions and other post-retirement benefit obligations	Jun. 30, 2023
Post-retirement and other defined benefit schemes
Pensions and other post-retirement benefit obligations	Note 5: Pensions and other post-retirement benefit obligations During the six months ended 30 June 2023, AstraZeneca Pharmaceuticals PLP terminated its main defined benefit pension plan. A total of $839m of pension obligations were discharged from the scheme, $142m of which was settled via a cash payment to the participants and the remaining $697m was transferred to an external insurer via a buy-out. At 30 June 2023, the plan contained immaterial residual assets and obligations which are expected to be discharged by the end of 2023, with minimal impact to the income statement.

Legal proceedings and contingen

Legal proceedings and contingent liabilities	6 Months Ended
Legal proceedings and contingent liabilities	Jun. 30, 2023
Legal proceedings and contingent liabilities
Legal proceedings and contingent liabilities	Note 6: Legal proceedings and contingent liabilities AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and investigations, including Government investigations, relating to product liability, commercial disputes, infringement of intellectual property (IP) rights, the validity of certain patents, anti-trust law and sales and marketing practices. The matters discussed below constitute the more significant developments since publication of the disclosures concerning legal proceedings in the Company's Annual Report and Form 20-F Information 2022 (the Disclosures). As discussed in the Disclosures, the majority of claims involve highly complex issues. Often these issues are subject to substantial uncertainties and, therefore, the probability of a loss, if any, being sustained and/or an estimate of the amount of any loss is difficult to ascertain. Unless There is one matter concerning legal proceedings in the Disclosures, which is considered probable that an outflow will be required, but for which we are unable to make an estimate of the possible loss or range of possible losses at this stage. In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed and which are not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate of the loss, AstraZeneca records the loss absorbed or makes a provision for its best estimate of the expected loss. The position could change over time and the estimates that the Company made, and upon which the Company have relied in calculating these provisions are inherently imprecise. There can, therefore, be no assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of the provisions that have been booked in the accounts. The major factors causing this uncertainty are described more fully in the Disclosures and herein. AstraZeneca has full confidence in, and will vigorously defend and enforce, its IP. Matters disclosed in respect of the second quarter of 2023 and to 28 July 2023 Patent litigation Imfinzi and Imjudo Patent proceedings in the US and outside the US As previously disclosed, in March 2022, Bristol-Myers Squibb Co. and E.R. Squibb & Sons, LLC filed a lawsuit in US District Court for the District of Delaware (the District Court) against AstraZeneca alleging that AstraZeneca’s marketing of Imfinzi Imfinzi As previously disclosed, in January 2023, Bristol-Myers Squibb Co. and E.R. Squibb & Sons, LLC filed a lawsuit in US District Court for the District of Delaware against AstraZeneca alleging that AstraZeneca’s marketing of Imjudo As previously disclosed, in February 2022, in Japan, Ono Pharmaceuticals filed a lawsuit in Tokyo District Court, Civil Division against AstraZeneca alleging that AstraZeneca’s marketing of Imfinzi In July 2023, AstraZeneca entered into a global settlement agreement with Bristol-Myers Squibb Co., E.R. Squibb & Sons, LLC, and Ono Pharmaceutical Co., Ltd. that resolves all patent disputes relating to Imfinzi Imjudo Imfinzi Imjudo Faslodex Patent proceedings outside the US As previously disclosed, in 2021 in Japan, AstraZeneca received notice from the Japan Patent Office (JPO) that Sandoz K.K. and Sun Pharma Japan Ltd. (Sun) were seeking to invalidate the Faslodex Product liability litigation Onglyza and Kombiglyze US proceedings In the US, AstraZeneca is defending various lawsuits alleging heart failure, cardiac injuries, and/or death from treatment with Onglyza Kombiglyze Commercial litigation AZD1222 Securities Litigation (US) In January 2021, putative securities class action lawsuits were filed in the US District Court for the Southern District of New York (the District Court) against AstraZeneca PLC and certain officers, on behalf of purchasers of AstraZeneca publicly traded securities during a period later amended to cover 15 June 2020 through 29 January 2021 (the Amended Complaint). The Amended Complaint alleges that defendants made materially false and misleading statements in connection with the development of AZD1222, AstraZeneca’s vaccine for the prevention of COVID-19. In September 2022, the District Court granted AstraZeneca’s motion to dismiss the Amended Complaint with prejudice, disallowing any further amendments. Plaintiffs appealed this decision and in May of 2023, the US Court of Appeals for the Second Circuit affirmed the dismissal. PARP Inhibitor Royalty Dispute In October 2012, Tesaro, Inc. (now wholly owned by GlaxoSmithKline plc, ‘GSK’) entered into two worldwide, royalty-bearing patent license agreements with AstraZeneca related to GSK’s product niraparib. In May 2021, AstraZeneca filed a lawsuit against GSK in the Commercial Court of England and Wales alleging that GSK has failed to pay all of the royalties due on niraparib sales under the license agreements. The case was transferred to the Chancery Division and a trial took place in March 2023. In April 2023, the court issued a decision in AstraZeneca’s favour. GSK has been granted permission to appeal. The appellate hearing window has been scheduled for January 2024. Syntimmune In connection with Alexion’s prior acquisition of Syntimmune, Inc., (Syntimmune) in December 2020, Alexion was served with a lawsuit filed by the stockholders’ representative for Syntimmune in Delaware State Court that alleged, among other things, breaches of contractual obligations relating to the 2018 merger agreement. The stockholders’ representative alleges that Alexion failed to meet its obligations under the merger agreement to use commercially reasonable efforts to achieve the milestones. Alexion also filed a claim for breach of the representations in the 2018 merger agreement. A trial was held in July 2023. A decision is not expected until 2024. Government investigations/proceedings US 340B litigations and proceedings As previously disclosed, in January 2021, AstraZeneca filed a separate lawsuit in the US District Court for the District of Delaware (the District Court) alleging that an Advisory Opinion issued by the Department of Health and Human Services violates the Administrative Procedure Act. In June 2021, the District Court found in favour of AstraZeneca, invalidating the Advisory Opinion. However, in May 2021, prior to the District Court’s ruling, the US government issued new and separate letters to AstraZeneca (and other companies) asserting that AstraZeneca’s contract pharmacy policy violates the 340B statute. AstraZeneca amended the complaint to include allegations challenging the letter sent in May 2021, and in February 2022, the District Court ruled in favour of AstraZeneca invalidating those letters sent by the US Government. In January 2023, the Court of Appeals affirmed the District Court decision in AstraZeneca’s favour. Final judgment was entered in favour of AstraZeneca in May 2023 and this matter is now concluded. Matters disclosed in respect of the first quarter of 2023 and to 27 April 2023 Patent Enhertu US As Lynparza US As previously disclosed, in December 2022, AstraZeneca received a Paragraph IV notice letter from an abbreviated Lynparza Lynparza Lynparza Movantik US patent proceedings AstraZeneca Movantik Symbicort US AstraZeneca Symbicort Tagrisso Patent US In Russia, in October 2021, AstraZeneca filed a lawsuit in the Arbitration Court of the Moscow Region (the Court) Tagrisso Tagrisso Product litigation Nexium and Losec / Prilosec US proceedings In the US, AstraZeneca is defending various previously disclosed lawsuits brought in federal and state courts involving Nexium Prilosec In addition, AstraZeneca has been defending various lawsuits involving allegations of gastric cancer following treatment with proton Nexium Prilosec Onglyza and Kombiglyze US proceedings As previously disclosed, in the US, AstraZeneca is defending various lawsuits alleging heart failure, cardiac injuries, and/or death from treatment with Onglyza Kombiglyze Commercial Litigation Viela Bio, Inc. Shareholder Litigation US In Definiens In Germany, in July 2020, AstraZeneca received a notice of PARP Inhibitor Royalty Dispute In October 2012, Tesaro, Inc. (now wholly owned by GlaxoSmithKline plc, ‘GSK’) entered into two worldwide, royalty-bearing patent license agreements with AstraZeneca related to GSK’s product niraparib. In May 2021, AstraZeneca Pay Equity Litigation (US) AstraZeneca Portola Shareholder Litigation In Andexxa Alexion Shareholder Litigation (US) In Soliris Financial State me nts Syntimmune In connection with Alexion’s prior acquisition of Syntimmune, Inc., (Syntimmune) in December 2020, Alexion was Government investigations/proceedings Brazilian tax assessment matter (Brazil) As previously disclosed, in August 2019, the Brazilian Federal Revenue Service provided a Notice of Tax and Description of the Facts (the Tax Assessment) to two Alexion subsidiaries (the Brazil Subsidiaries), as well as to two additional entities, a logistics provider utilised by Alexion and a distributor. The Tax Assessment focuses on the importation of Soliris Alexion prevailed in the first level of administrative appeals in the Brazilian federal administrative proceeding system based on a deficiency in the Brazil Tax Assessment. The decision was subject to an automatic (ex officio) appeal to the second level of the administrative courts. In March 2023, the second level of the administrative courts issued a decision to remand the matter to the first level of administrative courts for a determination on the merits.

Subsequent Events

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2023
Subsequent Events
Subsequent Events	Note 7 : Subsequent events In July 2023, Alexion, AstraZeneca Rare Disease (Alexion) and Pfizer Inc. (Pfizer) entered into an agreement for Alexion to purchase and licence the assets of Pfizer’s early-stage rare disease gene therapy portfolio for a total consideration of up to $1bn, plus tiered royalties on sales. Alexion plans to close the transaction in Q3 2023, subject to the satisfaction of closing conditions.

H1 2023 - Product Sales year-on

H1 2023 - Product Sales year-on-year analysis	6 Months Ended
H1 2023 - Product Sales year-on-year analysis	Jun. 30, 2023
Additional financial information
H1 2023 - Product Sales year-on-year analysis	Note : Additional financial information Table 27: H1 2023 - Product Sales year-on-year analysis 80 The CER information in respect of H1 2023 included in the Interim Financial Statements has not been reviewed by PricewaterhouseCoopers LLP. World US Emerging Markets Europe Established RoW $m Act % chg CER % chg $m % chg $m Act % chg CER % chg $m Act % chg CER % chg $m Act % chg CER % chg Oncology 8,302 17 21 3,666 23 1,953 9 17 1,579 18 21 1,104 13 25 Tagrisso 2,915 8 12 1,102 16 851 6 13 541 6 9 421 (4) 6 Imfinzi 1,976 53 57 1,098 60 183 37 47 339 27 30 356 74 92 Lynparza 1,368 6 10 580 - 278 15 23 365 11 14 145 5 15 Calquence 1,185 31 33 869 18 41 n/m n/m 225 85 92 50 64 75 Enhertu 104 n/m n/m - - 72 n/m n/m 24 n/m n/m 8 n/m n/m Orpathys 22 (7) - - - 22 (7) - - - - - - - Zoladex 459 (4) 4 6 (3) 339 2 11 66 (3) 1 48 (32) (24) Faslodex 153 (14) (7) 7 (37) 81 - 7 16 (50) (48) 49 (10) 1 Others 120 (37) (33) 4 (26) 86 (39) (35) 3 (53) (51) 27 (28) (22) BioPharmaceuticals: CVRM 5,205 14 19 1,283 11 2,347 12 20 1,168 24 27 407 12 23 Farxiga 2,804 33 39 634 35 1,074 32 41 850 36 40 246 27 39 Brilinta 665 (1) 1 357 2 160 10 17 136 (9) (7) 12 (57) (53) Lokelma 198 53 59 105 35 24 n/m n/m 25 98 n/m 44 32 47 roxadustat 134 48 59 - - 134 48 59 - - - - - - Andexxa 89 28 33 37 (12) - - - 29 64 70 23 n/m n/m Crestor 585 7 14 26 (23) 458 11 18 32 52 54 69 (11) (3) Seloken Toprol-XL 343 (27) (20) 1 n/m 333 (27) (21) 6 (6) (6) 3 (26) (11) Onglyza 127 (8) (4) 36 (11) 67 1 9 16 (21) (18) 8 (31) (28) Bydureon 89 (37) (37) 73 (38) 2 (1) - 14 (32) (30) - - - Others 171 (13) (10) 14 (26) 95 (9) (3) 60 (13) (13) 2 (57) (53) BioPharmaceuticals: R&I 3,066 6 10 1,291 (1) 893 22 31 581 6 9 301 (3) 6 Symbicort 1,288 - 4 434 (10) 405 32 43 284 (9) (6) 165 (13) (6) Fasenra 744 12 14 468 12 29 66 70 176 15 19 71 (2) 7 Breztri 307 71 76 165 55 81 88 n/m 36 n/m n/m 25 53 65 Saphnelo 115 n/m n/m 107 n/m 1 n/m n/m 3 n/m n/m 4 n/m n/m Tezspire 30 n/m n/m - - - - - 17 n/m n/m 13 n/m n/m Pulmicort 346 4 11 17 (54) 273 16 24 36 2 6 20 (23) (17) Bevespi 29 (1) (1) 17 (23) 3 36 48 9 67 69 - - - Daliresp Daxas 30 (72) (72) 24 (77) 1 (16) (14) 5 (11) (5) - (39) (36) Others 177 (30) (26) 59 (40) 100 (20) (13) 15 (42) (39) 3 (3) - BioPharmaceuticals: V&I 443 (84) (83) - n/m 149 (83) (82) 114 (78) (77) 180 (75) (72) COVID-19 mAbs 126 (86) (85) - n/m 5 (95) (95) 7 (95) (95) 114 (6) 6 Vaxzevria 28 (98) (98) - n/m 18 (97) (97) 10 (96) (96) - n/m n/m Beyfortus 2 n/m n/m - - - - - 2 n/m n/m - - - Synagis 284 1 8 - n/m 126 17 23 92 (13) (9) 66 3 15 FluMist 3 n/m n/m - n/m - - - 3 n/m n/m - - - Rare Disease 3,819 9 12 2,290 10 324 57 67 767 5 8 438 (6) 4 Soliris 1,648 (18) (16) 893 (23) 214 60 76 367 (16) (14) 174 (38) (33) Ultomiris 1,364 60 64 815 79 30 - 2 311 38 42 208 46 62 Strensiq 562 25 26 453 28 24 33 26 42 5 8 43 12 23 Koselugo 159 57 57 89 15 38 n/m n/m 23 n/m n/m 9 - - Kanuma 86 16 17 40 4 18 95 96 24 5 7 4 12 22 Other medicines 613 (27) (22) 68 (9) 390 (1) 6 48 (28) (27) 107 (65) (61) Nexium 492 (27) (22) 60 (6) 305 6 14 25 (4) (2) 102 (65) (62) Others 121 (28) (25) 8 (26) 85 (20) (15) 23 (44) (44) 5 (49) (47) Total Product Sales 21,448 (1) 3 8,598 4 6,056 - 7 4,257 3 6 2,537 (19) (11) 80 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.

Q2 2023 Product Sales year-on-y

Q2 2023 Product Sales year-on-year analysis	6 Months Ended
Q2 2023 Product Sales year-on-year analysis	Jun. 30, 2023
Q2 2023 Product Sales year-on-year analysis
Q2 2023 Product Sales year-on-year analysis	Table 28: Q2 2023 - Product Sales year-on-year analysis (Unreviewed) 81 The Q2 2023 information in respect of the three months ended 30 June 2023 included in the Interim Financial Statements has not been reviewed by PricewaterhouseCoopers LLP. World US Emerging Markets Europe Established RoW $m Act % chg CER % chg $m % chg $m Act % chg CER % chg $m Act % chg CER % chg $m Act % chg CER % chg Oncology 4,382 18 22 1,962 22 987 10 18 819 19 19 614 21 30 Tagrisso 1,491 7 10 581 13 408 2 9 284 11 11 218 (6) 2 Imfinzi 1,076 55 58 576 54 102 35 47 176 23 23 222 n/m n/m Lynparza 717 7 9 311 - 142 18 28 187 10 11 77 7 15 Calquence 653 34 34 485 22 24 n/m n/m 117 76 78 27 55 64 Enhertu 67 n/m n/m - - 48 n/m n/m 14 n/m n/m 5 n/m n/m Orpathys 13 22 30 - - 13 22 30 - - - - - - Zoladex 233 (1) 5 4 25 171 4 13 34 (1) 1 24 (31) (26) Faslodex 78 (8) (3) 3 (41) 43 16 23 6 (61) (62) 26 (6) 1 Others 54 (42) (39) 2 (24) 36 (48) (44) 1 (50) (51) 15 (24) (21) BioPharmaceuticals: CVRM 2,675 14 18 661 5 1,182 10 18 611 32 33 221 19 27 Farxiga 1,505 36 41 339 23 576 36 45 456 48 48 134 39 50 Brilinta 331 (5) (3) 178 (4) 79 1 10 68 (7) (7) 6 (55) (53) Lokelma 100 51 55 49 26 13 n/m n/m 14 98 n/m 24 34 44 roxadustat 73 46 56 - - 73 46 56 - - - - - - Andexxa 45 23 26 16 (10) - - - 15 70 74 14 44 49 Crestor 280 - 5 12 (25) 217 - 6 16 56 51 35 (4) 2 Seloken Toprol-XL 164 (26) (21) 1 - 159 (27) (21) 2 (16) (9) 2 (28) (2) Onglyza 65 (9) (6) 22 1 30 (7) - 8 (24) (18) 5 (30) (37) Bydureon 43 (41) (41) 35 (43) 1 (33) (32) 7 (25) (25) - - - Others 69 (30) (28) 9 (26) 34 (35) (31) 25 (23) (23) 1 (50) (46) BioPharmaceuticals: R&I 1,483 7 10 674 3 360 22 31 289 6 6 160 1 8 Symbicort 600 (2) 1 200 (10) 177 27 37 137 (11) (11) 86 (12) (5) Fasenra 406 15 16 267 16 14 37 42 89 14 14 36 - 8 Breztri 163 75 79 84 57 43 n/m n/m 21 n/m n/m 15 54 60 Saphnelo 68 n/m n/m 64 n/m 1 n/m n/m 1 n/m n/m 2 n/m n/m Tezspire 19 n/m n/m - - - - - 11 n/m n/m 8 n/m n/m Pulmicort 124 7 13 7 (53) 90 26 36 16 (7) (7) 11 (14) (8) Bevespi 15 (1) (3) 8 (30) 2 76 90 5 77 73 - - - Daliresp Daxas 17 (71) (70) 14 (74) 1 (13) (10) 2 (15) (8) - - - Others 71 (34) (32) 30 (35) 32 (36) (32) 7 (20) (18) 2 6 5 BioPharmaceuticals: V&I 88 (91) (90) - n/m 46 (80) (78) 15 (93) (93) 27 (90) (89) COVID-19 mAbs (1) n/m n/m - n/m (3) n/m n/m 3 (96) (97) (1) n/m n/m Vaxzevria - n/m n/m - n/m - n/m n/m - n/m n/m - n/m n/m Beyfortus 2 n/m n/m - - - - - 2 n/m n/m - - - Synagis 87 8 16 - n/m 49 16 27 10 (48) (47) 28 63 75 FluMist - n/m n/m - n/m - - - - n/m n/m - - - Rare Disease 1,953 8 10 1,196 12 150 65 78 381 2 2 226 (15) (9) Soliris 814 (21) (19) 445 (23) 99 57 74 184 (15) (15) 86 (50) (47) Ultomiris 713 64 66 434 84 17 n/m n/m 152 26 26 110 53 64 Strensiq 300 24 25 248 29 9 (1) (4) 21 - (1) 22 16 25 Koselugo 80 28 30 48 2 14 36 38 12 n/m n/m 6 n/m n/m Kanuma 46 28 30 21 5 11 n/m n/m 12 5 4 2 (4) 3 Other medicines 301 (28) (24) 32 (11) 185 (3) 4 26 (16) (17) 58 (64) (61) Nexium 248 (28) (23) 30 - 149 3 11 14 16 15 55 (65) (62) Others 53 (29) (27) 2 (68) 36 (22) (18) 12 (36) (36) 3 (28) (31) Total Product Sales 10,882 2 5 4,525 7 2,910 5 12 2,141 4 4 1,306 (16) (9) 81 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.

Alliance Revenue

Alliance Revenue	6 Months Ended
Alliance Revenue	Jun. 30, 2023
Alliance revenue [Abstract]
Alliance revenue	Table 29: Alliance Revenue H1 2023 H1 2022 $m $m Enhertu 475 175 Tezspire 105 16 Vaxzevria - 60 Other royalty income 41 34 Other Alliance Revenue 6 5 Total 627 290

Collaboration Revenue

Collaboration Revenue	6 Months Ended
Collaboration Revenue	Jun. 30, 2023
Collaboration Revenue.
Collaboration Revenue	Table 30: Collaboration Revenue H1 2023 H1 2022 $m $m Lynparza : regulatory milestones - 175 COVID-19 mAbs: licence fees 180 - Farxiga 25 - tralokinumab: sales milestones - 70 Other Collaboration Revenue 15 16 Total 220 261

Other operating income and expe

Other operating income and expense	6 Months Ended
Other operating income and expense	Jun. 30, 2023
Other operating income and expense
Other operating income and expense	Table 31: Other operating income and expense H1 2023 H1 2022 $m $m brazikumab licence termination funding 75 69 Divestment of rights to Plendil - 61 Divestment of US rights to Pulmicort Flexhaler 241 - Update to the contractual relationships for Beyfortus (nirsevimab) 712 - Other 135 89 Total 1,163 219

Basis of preparation and acco_2

Basis of preparation and accounting policies (Policies)	6 Months Ended
Basis of preparation and accounting policies (Policies)	Jun. 30, 2023
Basis of preparation and accounting policies
Basis of preparation and accounting policies	These unaudited condensed consolidated Interim Financial Statements for the six months ended 30 June 2023 have been prepared in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’ (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union, UK-adopted IAS 34 and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority and with the requirements of the Companies Act 2006 as applicable to companies reporting under those standards. The unaudited Interim Financial Statements for the six months ended 30 June 2023 were approved by the Board of Directors for publication on 28 July 2023. This results announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The annual financial statements of the Group for the year ended 31 December 2022 were prepared in accordance with UK-adopted International Accounting Standards and with the requirements of the Companies Act 2006. The annual financial statements also comply fully with IFRSs as issued by the IASB and International Accounting Standards as adopted by the European Union. Except for the estimation of the interim income tax charge, the Interim Financial Statements have been prepared applying the accounting policies that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2022. The comparative figures for the financial year ended 31 December 2022 are not the Group’s statutory accounts for that financial year. Those accounts have been reported on by the Group’s auditors and have been delivered to the registrar of companies; their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006.
Alliance and collaboration revenue	Alliance and Collaboration Revenues Effective 1 January 2023, the Group has updated the presentation of Total Revenue on the face of the Statement of Comprehensive Income to include Alliance Revenue as a separate element to Collaboration Revenue. Alliance Revenue, previously reported within Collaboration Revenue, comprises income related to sales made by collaboration partners, where AstraZeneca is entitled to a profit share, revenue share or royalties, which are recurring in nature while the collaboration arrangement remains in place. Alliance Revenue does not include Product Sales where AstraZeneca is leading commercialisation in a territory. Collaboration Revenue arising from collaborative arrangements where the Group retains a significant ongoing economic interest and receives upfront amounts and event-triggered milestones, which arise from the licensing of intellectual property, will continue to be reported as Collaboration Revenue. In collaboration arrangements either AstraZeneca or the collaborator acts as principal in sales to the end customer. Where AstraZeneca acts as principal, we record 100% of sales to the end customer within Product Sales. The revised presentation reflects the increasing importance of income arising from profit share arrangements where collaboration partners are responsible for booking revenues in some or all territories. The comparative revenue reported in H1 2023 relating to the half year to 30 June 2022 has been retrospectively adjusted to reflect the new split of Total Revenue, resulting in Alliance Revenue being reported for the half year 30 June 2022 of $290m, however the combined total of Alliance Revenue and Collaboration Revenue is equal to the previously reported Collaboration Revenue total for the half year 30 June 2022.
Going concern	Going concern The Group has considerable financial resources available. As at 30 June 2023, the Group has $12.6bn in financial resources (Cash and cash equivalent balances of $5.7bn and undrawn committed bank facilities of $6.9bn available, of which $2.0bn of the facilities are available until February 2025 and the other $4.9bn are available until April 2026, with $4.6bn of borrowings due within one year). These facilities contain no financial covenants and were undrawn at 30 June 2023. The Group’s revenues are largely derived from sales of medicines covered by patents which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in some of our significant markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. Accordingly, they continue to adopt the going concern basis in preparing the Interim Financial Statements.
Legal proceedings	Legal proceedings The information contained in Note 6 updates the disclosures concerning legal proceedings and contingent liabilities in the Group’s Annual Report and Form 20-F Information 202 2.
IAS 12 'Income Taxes'	IAS 12 ‘Income Taxes’ On 25 May 2023, the IASB issued an amendment to IAS 12 ‘Income Taxes’ to clarify how the effects of the global minimum tax framework should be accounted for and disclosed effective 1 January 2023. This was endorsed by the UK Endorsement Board on 19 July 2023 and has been adopted by the Company for 2023 reporting. The Company has applied the exemption to recognising and disclosing information about deferred tax assets and liabilities related to Pillar 2 income taxes. The Company is currently assessing the potential impact of these draft rules upon its financial statements.

Net Debt (Tables)

Net Debt (Tables)	6 Months Ended
Net Debt (Tables)	Jun. 30, 2023
Net Debt.
Schedule of Net Debt	At 1 Jan Cash Non-cash Exchange At 30 Jun 2023 flow Acquisitions & other movements 2023 $m $m $m $m $m $m Non-current instalments of loans (22,965) (3,827) - 2,587 (124) (24,329) Non-current instalments of leases (725) (1) (6) 10 - (722) Total long-term debt (23,690) (3,828) (6) 2,597 (124) (25,051) Current instalments of loans (4,964) 3,409 - (2,594) 14 (4,135) Current instalments of leases (228) 141 (2) (146) 4 (231) Bank collateral received (89) (61) - - - (150) Other short-term borrowings excluding overdrafts (78) (11) - - 11 (78) Overdrafts (183) (10) - - - (193) Total current debt (5,542) 3,468 (2) (2,740) 29 (4,787) Gross borrowings (29,232) (360) (8) (143) (95) (29,838) Net derivative financial instruments (96) (27) - 179 - 56 Net borrowings (29,328) (387) (8) 36 (95) (29,782) Cash and cash equivalents 6,166 (455) - - (47) 5,664 Other investments - current 239 (90) - - (1) 148 Cash and investments 6,405 (545) - - (48) 5,812 Net debt (22,923) (932) (8) 36 (143) (23,970)

Financial instruments (Tables)

Financial instruments (Tables)	6 Months Ended
Financial instruments (Tables)	Jun. 30, 2023
Financial instruments
Schedule of Contingent consideration	2023 2022 Diabetes alliance Other Total Total $m $m $m $m At 1 January 2,124 98 2,222 2,865 Additions through business combinations - 60 60 - Settlements (395) (3) (398) (367) Disposals - - - (121) Revaluations 229 (27) 202 293 Discount unwind 62 4 66 85 At 30 June 2,020 132 2,152 2,755

H1 2023 - Product Sales year-_2

H1 2023 - Product Sales year-on-year analysis (Tables)	6 Months Ended
H1 2023 - Product Sales year-on-year analysis (Tables)	Jun. 30, 2023
Additional financial information
H1 2023 Product Sales year-on-year analysis	World US Emerging Markets Europe Established RoW $m Act % chg CER % chg $m % chg $m Act % chg CER % chg $m Act % chg CER % chg $m Act % chg CER % chg Oncology 8,302 17 21 3,666 23 1,953 9 17 1,579 18 21 1,104 13 25 Tagrisso 2,915 8 12 1,102 16 851 6 13 541 6 9 421 (4) 6 Imfinzi 1,976 53 57 1,098 60 183 37 47 339 27 30 356 74 92 Lynparza 1,368 6 10 580 - 278 15 23 365 11 14 145 5 15 Calquence 1,185 31 33 869 18 41 n/m n/m 225 85 92 50 64 75 Enhertu 104 n/m n/m - - 72 n/m n/m 24 n/m n/m 8 n/m n/m Orpathys 22 (7) - - - 22 (7) - - - - - - - Zoladex 459 (4) 4 6 (3) 339 2 11 66 (3) 1 48 (32) (24) Faslodex 153 (14) (7) 7 (37) 81 - 7 16 (50) (48) 49 (10) 1 Others 120 (37) (33) 4 (26) 86 (39) (35) 3 (53) (51) 27 (28) (22) BioPharmaceuticals: CVRM 5,205 14 19 1,283 11 2,347 12 20 1,168 24 27 407 12 23 Farxiga 2,804 33 39 634 35 1,074 32 41 850 36 40 246 27 39 Brilinta 665 (1) 1 357 2 160 10 17 136 (9) (7) 12 (57) (53) Lokelma 198 53 59 105 35 24 n/m n/m 25 98 n/m 44 32 47 roxadustat 134 48 59 - - 134 48 59 - - - - - - Andexxa 89 28 33 37 (12) - - - 29 64 70 23 n/m n/m Crestor 585 7 14 26 (23) 458 11 18 32 52 54 69 (11) (3) Seloken Toprol-XL 343 (27) (20) 1 n/m 333 (27) (21) 6 (6) (6) 3 (26) (11) Onglyza 127 (8) (4) 36 (11) 67 1 9 16 (21) (18) 8 (31) (28) Bydureon 89 (37) (37) 73 (38) 2 (1) - 14 (32) (30) - - - Others 171 (13) (10) 14 (26) 95 (9) (3) 60 (13) (13) 2 (57) (53) BioPharmaceuticals: R&I 3,066 6 10 1,291 (1) 893 22 31 581 6 9 301 (3) 6 Symbicort 1,288 - 4 434 (10) 405 32 43 284 (9) (6) 165 (13) (6) Fasenra 744 12 14 468 12 29 66 70 176 15 19 71 (2) 7 Breztri 307 71 76 165 55 81 88 n/m 36 n/m n/m 25 53 65 Saphnelo 115 n/m n/m 107 n/m 1 n/m n/m 3 n/m n/m 4 n/m n/m Tezspire 30 n/m n/m - - - - - 17 n/m n/m 13 n/m n/m Pulmicort 346 4 11 17 (54) 273 16 24 36 2 6 20 (23) (17) Bevespi 29 (1) (1) 17 (23) 3 36 48 9 67 69 - - - Daliresp Daxas 30 (72) (72) 24 (77) 1 (16) (14) 5 (11) (5) - (39) (36) Others 177 (30) (26) 59 (40) 100 (20) (13) 15 (42) (39) 3 (3) - BioPharmaceuticals: V&I 443 (84) (83) - n/m 149 (83) (82) 114 (78) (77) 180 (75) (72) COVID-19 mAbs 126 (86) (85) - n/m 5 (95) (95) 7 (95) (95) 114 (6) 6 Vaxzevria 28 (98) (98) - n/m 18 (97) (97) 10 (96) (96) - n/m n/m Beyfortus 2 n/m n/m - - - - - 2 n/m n/m - - - Synagis 284 1 8 - n/m 126 17 23 92 (13) (9) 66 3 15 FluMist 3 n/m n/m - n/m - - - 3 n/m n/m - - - Rare Disease 3,819 9 12 2,290 10 324 57 67 767 5 8 438 (6) 4 Soliris 1,648 (18) (16) 893 (23) 214 60 76 367 (16) (14) 174 (38) (33) Ultomiris 1,364 60 64 815 79 30 - 2 311 38 42 208 46 62 Strensiq 562 25 26 453 28 24 33 26 42 5 8 43 12 23 Koselugo 159 57 57 89 15 38 n/m n/m 23 n/m n/m 9 - - Kanuma 86 16 17 40 4 18 95 96 24 5 7 4 12 22 Other medicines 613 (27) (22) 68 (9) 390 (1) 6 48 (28) (27) 107 (65) (61) Nexium 492 (27) (22) 60 (6) 305 6 14 25 (4) (2) 102 (65) (62) Others 121 (28) (25) 8 (26) 85 (20) (15) 23 (44) (44) 5 (49) (47) Total Product Sales 21,448 (1) 3 8,598 4 6,056 - 7 4,257 3 6 2,537 (19) (11)

Q2 2023 Product Sales year-on_2

Q2 2023 Product Sales year-on-year analysis (Tables)	6 Months Ended
Q2 2023 Product Sales year-on-year analysis (Tables)	Jun. 30, 2023
Q2 2023 Product Sales year-on-year analysis
Q2 2023 Product Sales year-on-year analysis	World US Emerging Markets Europe Established RoW $m Act % chg CER % chg $m % chg $m Act % chg CER % chg $m Act % chg CER % chg $m Act % chg CER % chg Oncology 4,382 18 22 1,962 22 987 10 18 819 19 19 614 21 30 Tagrisso 1,491 7 10 581 13 408 2 9 284 11 11 218 (6) 2 Imfinzi 1,076 55 58 576 54 102 35 47 176 23 23 222 n/m n/m Lynparza 717 7 9 311 - 142 18 28 187 10 11 77 7 15 Calquence 653 34 34 485 22 24 n/m n/m 117 76 78 27 55 64 Enhertu 67 n/m n/m - - 48 n/m n/m 14 n/m n/m 5 n/m n/m Orpathys 13 22 30 - - 13 22 30 - - - - - - Zoladex 233 (1) 5 4 25 171 4 13 34 (1) 1 24 (31) (26) Faslodex 78 (8) (3) 3 (41) 43 16 23 6 (61) (62) 26 (6) 1 Others 54 (42) (39) 2 (24) 36 (48) (44) 1 (50) (51) 15 (24) (21) BioPharmaceuticals: CVRM 2,675 14 18 661 5 1,182 10 18 611 32 33 221 19 27 Farxiga 1,505 36 41 339 23 576 36 45 456 48 48 134 39 50 Brilinta 331 (5) (3) 178 (4) 79 1 10 68 (7) (7) 6 (55) (53) Lokelma 100 51 55 49 26 13 n/m n/m 14 98 n/m 24 34 44 roxadustat 73 46 56 - - 73 46 56 - - - - - - Andexxa 45 23 26 16 (10) - - - 15 70 74 14 44 49 Crestor 280 - 5 12 (25) 217 - 6 16 56 51 35 (4) 2 Seloken Toprol-XL 164 (26) (21) 1 - 159 (27) (21) 2 (16) (9) 2 (28) (2) Onglyza 65 (9) (6) 22 1 30 (7) - 8 (24) (18) 5 (30) (37) Bydureon 43 (41) (41) 35 (43) 1 (33) (32) 7 (25) (25) - - - Others 69 (30) (28) 9 (26) 34 (35) (31) 25 (23) (23) 1 (50) (46) BioPharmaceuticals: R&I 1,483 7 10 674 3 360 22 31 289 6 6 160 1 8 Symbicort 600 (2) 1 200 (10) 177 27 37 137 (11) (11) 86 (12) (5) Fasenra 406 15 16 267 16 14 37 42 89 14 14 36 - 8 Breztri 163 75 79 84 57 43 n/m n/m 21 n/m n/m 15 54 60 Saphnelo 68 n/m n/m 64 n/m 1 n/m n/m 1 n/m n/m 2 n/m n/m Tezspire 19 n/m n/m - - - - - 11 n/m n/m 8 n/m n/m Pulmicort 124 7 13 7 (53) 90 26 36 16 (7) (7) 11 (14) (8) Bevespi 15 (1) (3) 8 (30) 2 76 90 5 77 73 - - - Daliresp Daxas 17 (71) (70) 14 (74) 1 (13) (10) 2 (15) (8) - - - Others 71 (34) (32) 30 (35) 32 (36) (32) 7 (20) (18) 2 6 5 BioPharmaceuticals: V&I 88 (91) (90) - n/m 46 (80) (78) 15 (93) (93) 27 (90) (89) COVID-19 mAbs (1) n/m n/m - n/m (3) n/m n/m 3 (96) (97) (1) n/m n/m Vaxzevria - n/m n/m - n/m - n/m n/m - n/m n/m - n/m n/m Beyfortus 2 n/m n/m - - - - - 2 n/m n/m - - - Synagis 87 8 16 - n/m 49 16 27 10 (48) (47) 28 63 75 FluMist - n/m n/m - n/m - - - - n/m n/m - - - Rare Disease 1,953 8 10 1,196 12 150 65 78 381 2 2 226 (15) (9) Soliris 814 (21) (19) 445 (23) 99 57 74 184 (15) (15) 86 (50) (47) Ultomiris 713 64 66 434 84 17 n/m n/m 152 26 26 110 53 64 Strensiq 300 24 25 248 29 9 (1) (4) 21 - (1) 22 16 25 Koselugo 80 28 30 48 2 14 36 38 12 n/m n/m 6 n/m n/m Kanuma 46 28 30 21 5 11 n/m n/m 12 5 4 2 (4) 3 Other medicines 301 (28) (24) 32 (11) 185 (3) 4 26 (16) (17) 58 (64) (61) Nexium 248 (28) (23) 30 - 149 3 11 14 16 15 55 (65) (62) Others 53 (29) (27) 2 (68) 36 (22) (18) 12 (36) (36) 3 (28) (31) Total Product Sales 10,882 2 5 4,525 7 2,910 5 12 2,141 4 4 1,306 (16) (9)

Alliance Revenue (Tables)

Alliance Revenue (Tables)	6 Months Ended
Alliance Revenue (Tables)	Jun. 30, 2023
Alliance revenue [Abstract]
Schedule of alliance revenue	H1 2023 H1 2022 $m $m Enhertu 475 175 Tezspire 105 16 Vaxzevria - 60 Other royalty income 41 34 Other Alliance Revenue 6 5 Total 627 290

Collaboration Revenue (Tables)

Collaboration Revenue (Tables)	6 Months Ended
Collaboration Revenue (Tables)	Jun. 30, 2023
Collaboration Revenue.
Schedule of collaboration revenue	H1 2023 H1 2022 $m $m Lynparza : regulatory milestones - 175 COVID-19 mAbs: licence fees 180 - Farxiga 25 - tralokinumab: sales milestones - 70 Other Collaboration Revenue 15 16 Total 220 261

Other operating income and ex_2

Other operating income and expense (Tables)	6 Months Ended
Other operating income and expense (Tables)	Jun. 30, 2023
Other operating income and expense
Schedule of other operating income and expense	H1 2023 H1 2022 $m $m brazikumab licence termination funding 75 69 Divestment of rights to Plendil - 61 Divestment of US rights to Pulmicort Flexhaler 241 - Update to the contractual relationships for Beyfortus (nirsevimab) 712 - Other 135 89 Total 1,163 219

Basis of preparation and acco_3

Basis of preparation and accounting policies (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2023		Jun. 30, 2022	Jun. 30, 2023		Jun. 30, 2022	Dec. 31, 2022
Disclosure of detailed information about borrowings [line items]
Alliance revenue	$ 341	[1]	$ 138	$ 627		$ 290
Percentage of sales recorded within product sales when entity acts as principal				100%
Borrowings	29,838			$ 29,838			$ 29,232
Going concern
Financial resources	12,600			12,600
Cash and cash equivalents	5,664	[2]	$ 4,817	5,664	[2]	$ 4,817	$ 6,166
Undrawn committed bank facilities	6,900			6,900
February 2025
Going concern
Undrawn committed bank facilities	2,000			2,000
April 2026
Going concern
Undrawn committed bank facilities	4,900			4,900
Due within one year
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 4,600			$ 4,600

[1] The Q2 2023 and Q2 2022 information in respect of the three months ended 30 June 2023 and 30 June 2022 respectively included in the Interim Financial Statements have not been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 30 June 2023 and 30 June 2022 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2022 has been audited by PricewaterhouseCoopers LLP.

Intangible assets - Net impairm

Intangible assets - Net impairment charges (reversals) (Details) - USD ($) $ in Millions		6 Months Ended
	Feb. 24, 2023	Jun. 30, 2023	Jun. 30, 2022	Jan. 16, 2023
Impairment of intangible assets
Payment for intangible assets		$ 1,436	$ 434
Neogene Therapeutics
Impairment of intangible assets
Total fair value of consideration				$ 267
Intangible assets				100
Goodwill recognised on acquisition				158
Cash transferred				189
Neogene Therapeutics \| Maximum
Impairment of intangible assets
Future payables for contingent milestones and non-contingent consideration				$ 120
CinCor
Impairment of intangible assets
Net assets acquired	$ 1,268
Intangible assets acquired	780
Cash and cash equivalents acquired	424
Marketable securities acquired	75
Payment for intangible assets	1,204
Contingent consideration liabilities recognised in asset acquisition	$ 496
Intangible assets other than goodwill
Impairment of intangible assets
Impairment loss (reversal of impairment loss)		320	(26)
Medicines in development
Impairment of intangible assets
Impairment loss (reversal of impairment loss)		320	$ (9)
ALXN1840
Impairment of intangible assets
Impairment loss (reversal of impairment loss)		$ 244

Net Debt (Details)

Net Debt (Details) - USD ($) $ in Millions		6 Months Ended
Net Debt (Details) - USD ($) $ in Millions		Jun. 30, 2023	Dec. 31, 2022
Interest bearing loans and borrowings
Non-current installments of loans at beginning of period		$ (22,965)
Non-current instalments of loans - Cash Flow		(3,827)
Non-current installments of loans - Non-cash & Other		2,587
Non-current installments of loans - Exchange Movements		(124)
Non-current installments of loans at end of period	[1]	(24,329)
Non-current installments of leases at beginning of period		(725)
Non-current instalments of leases - Cash Flow		(1)
Non-current instalments of leases - Acquisitions		(6)
Non-current installments of leases - Non-cash & Other		10
Non-current installments of leases at end of period	[1]	(722)
Total long-term debt at beginning of period		(23,690)
Total long-term debt - Cash Flow		(3,828)
Total long-term debt - Non-cash & Other		2,597
Total long-term debt - Acquisitions		(6)
Total long-term debt - Exchange Movements		(124)
Total long-term debt at end of period		(25,051)
Current instalments of loans at beginning of period		(4,964)
Current instalments of loans - Cash Flow		3,409
Current instalments of loans - Non-cash & Other		(2,594)
Current instalments of loans - Exchange Movements		14
Current instalments of loans at end of period		(4,135)
Current instalments of leases at beginning of period		(228)
Current instalments of leases - Cash Flow		141
Current instalments of leases - Acquisitions		(2)
Current instalments of leases - Non-cash & Other		(146)
Current instalments of leases - Exchange Movements		4
Current instalments of leases at end of period	[1]	(231)
Interest-bearing loans and borrowings at beginning of period		(5,314)
Interest-bearing loans and borrowings at end of period	[1]	(4,556)
Total current debt at beginning of period		(5,542)
Total current debt - Cash Flow		3,468
Total current debt - Acquisitions		(2)
Total current debt - Non-cash & Other		(2,740)
Total current debt - Exchange Movements		29
Total current debt at end of period		(4,787)
Gross borrowings at beginning of period		(29,232)
Gross borrowings - Cash Flow		(360)
Gross borrowings - Acquisitions		(8)
Gross borrowings - Non-cash & Other		(143)
Gross borrowings - Exchange Movements		(95)
Gross borrowings at end of period		(29,838)
Net derivative financial instruments at beginning of period		(96)
Net derivative financial instruments - Cash Flow		(27)
Net derivative financial instruments - Non-cash & Other		179
Net derivative financial instruments at end of period		56
Net borrowings at beginning of period		(29,328)
Net borrowings - Cash Flow		(387)
Net borrowings - Acquisitions		(8)
Net borrowings - Non-cash & Other		36
Net borrowings - Exchange Movements		(95)
Net borrowings at end of period		(29,782)
Cash and cash equivalents at the beginning of the period		6,166
Cash and cash equivalents - Cash Flow		(455)
Cash and cash equivalents - Exchange Movements		(47)
Cash and cash equivalents at the end of the period	[1]	5,664
Other investments - current at beginning of period		239
Other investments, current - Cash Flow		(90)
Other investments, current - Exchange Movements		(1)
Other investments - current at end of period	[1]	148
Cash and investments at beginning of period		6,405
Cash and investments - Cash Flow		(545)
Cash and investments - Exchange Movements		(48)
Cash and investments at end of period		5,812
Net debt at beginning of period		(22,923)
Net debt - Cash Flow		(932)
Net debt - Acquisitions		(8)
Net debt - Non-cash & Other		36
Net debt - Exchange Movements		(143)
Net debt at end of period		(23,970)
Cash collateral on financial derivatives		150	$ 89
Cash collateral posted by the Group		136	162
Increase (decrease) in net debt		1,047
Acerta Pharma
Interest bearing loans and borrowings
Share purchase liability		805	$ 1,646
Bank collateral received
Interest bearing loans and borrowings
Interest-bearing loans and borrowings at beginning of period		(89)
Current borrowings and current portion of non-current borrowing - Cash Flow		(61)
Interest-bearing loans and borrowings at end of period		(150)
Other Short-term borrowings excluding overdrafts
Interest bearing loans and borrowings
Interest-bearing loans and borrowings at beginning of period		(78)
Current borrowings and current portion of non-current borrowing - Cash Flow		(11)
Current borrowings and current portion of non-current borrowing - Exchange Movements		11
Interest-bearing loans and borrowings at end of period		(78)
Overdrafts
Interest bearing loans and borrowings
Interest-bearing loans and borrowings at beginning of period		(183)
Current borrowings and current portion of non-current borrowing - Cash Flow		(10)
Interest-bearing loans and borrowings at end of period		$ (193)

[1] The Condensed consolidated statement of financial position as at 30 June 2023 and 30 June 2022 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2022 has been audited by PricewaterhouseCoopers LLP.

Financial instruments (Details)

Financial instruments (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
Financial instruments (Details) - USD ($) $ in Millions	Jun. 30, 2023		Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Financial instruments fair value gains
Net gains on equity investments measured at fair value through other comprehensive income	$ (94)	[1]	$ (30)	$ (48)	$ (12)
Non-cash and other movements				(594)	(814)
Net cash inflow from operating activities				4,851	4,480
Reconciliation of changes in contingent liabilities in business combination
Contingent liabilities recognised in business combination at beginning of period				2,222	2,865
Additions				60
Settlements				(398)	(367)
Disposals					(121)
Revaluations				202	293
Discount unwind				66	85
Contingent liabilities recognised in business combination at end of period	2,152		$ 2,755	2,152	2,755
Change in royalty agreement concerning Beyfortus
Financial instruments fair value gains
Gains on elimination of payables				712
Diabetes alliance
Reconciliation of changes in contingent liabilities in business combination
Contingent liabilities recognised in business combination at beginning of period				2,124
Settlements				(395)
Revaluations				229
Discount unwind				62
Contingent liabilities recognised in business combination at end of period	2,020			2,020
Increase/decrease in contingent consideration balance with change in current estimates	202			$ 202
Percentage of reasonably possible increase or decrease in sales estimates				10%
Other
Reconciliation of changes in contingent liabilities in business combination
Contingent liabilities recognised in business combination at beginning of period				$ 98
Additions				60
Settlements				(3)
Revaluations				(27)
Discount unwind				4
Contingent liabilities recognised in business combination at end of period	132			132
Interest-Bearing Loans and Borrowings \| Not measured at fair value in statement of financial position but for which fair value is disclosed [member]
Financial instruments fair value gains
Carrying value, financial liabilities	29,838			29,838
Financial liabilities, at fair value	28,591			28,591
Financial assets at amortised cost
Financial instruments fair value gains
Cash collateral pledged to counterparties	136			136
Other Investments \| Financial assets measured at fair value
Financial instruments fair value gains
Financial assets.	1,083			1,083
Money market funds \| Financial assets measured at fair value
Financial instruments fair value gains
Financial assets.	4,400			4,400
Loans \| Financial assets designated as measured at fair value through profit or loss
Financial instruments fair value gains
Financial assets.	289			289
Derivatives \| Financial assets measured at fair value
Financial instruments fair value gains
Financial assets.	56			56
Level 3
Financial instruments fair value gains
Net gains on equity investments measured at fair value through other comprehensive income				1	$ 48
Level 3 \| Equity investments
Financial instruments fair value gains
Financial assets.	247			247		$ 186
Level 3 \| Equity warrants \| Financial assets measured at fair value
Financial instruments fair value gains
Financial assets.	$ 16			$ 16

[1] The Q2 2023 and Q2 2022 information in respect of the three months ended 30 June 2023 and 30 June 2022 respectively included in the Interim Financial Statements have not been reviewed by PricewaterhouseCoopers LLP.

Pensions and other post-retir_2

Pensions and other post-retirement benefit obligations (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2023		Jun. 30, 2022	Jun. 30, 2023		Jun. 30, 2022	Dec. 31, 2022
Post-retirement benefits
Net deficit position of pension schemes	$ 1,078	[1]	$ 1,310	$ 1,078	[1]	$ 1,310	$ 1,168
Actuarial gains reflected in comprehensive income statement	$ 17	[2]	$ 696	7		$ 1,031
AstraZeneca Pharmaceuticals LP main pension scheme
Post-retirement benefits
Amount of pension obligations discharged				(839)
Benefits paid				142
Obligations transferred to external insurers				$ 697

[1] The Condensed consolidated statement of financial position as at 30 June 2023 and 30 June 2022 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2022 has been audited by PricewaterhouseCoopers LLP. The Q2 2023 and Q2 2022 information in respect of the three months ended 30 June 2023 and 30 June 2022 respectively included in the Interim Financial Statements have not been reviewed by PricewaterhouseCoopers LLP.

Legal proceedings and conting_2

Legal proceedings and contingent liabilities - Legal proceedings (Details) $ in Millions	1 Months Ended
	Jul. 28, 2023 USD ($)	Mar. 31, 2023	Aug. 31, 2019 entity subsidiary	Jan. 31, 2023 patent	Jul. 31, 2020 USD ($)	Oct. 31, 2012
Legal proceedings after the end of reporting period \| Imfinzi and Imjudo US patent proceedings
Commitments and contingent liabilities
Amount of provisions made	$ 510
Imjudo patent proceedings
Commitments and contingent liabilities
Number of patents involved in patent proceedings \| patent				2
Legal proceedings \| PARP Inhibitor Royalty Dispute
Commitments and contingent liabilities
Number of disputed royalty-bearing patent license agreements						2
Legal proceedings \| Brazilian Tax Assessment Matter
Commitments and contingent liabilities
Number of subsidiaries involved in tax assessment matter \| subsidiary			2
Number of external entities involved in tax assessment matter \| entity			2
PARP Inhibitor Royalty Dispute
Commitments and contingent liabilities
Number of disputed royalty-bearing patent license agreements						2
Pay Equity Litigation
Commitments and contingent liabilities
Number of plaintiffs in case		3
Definiens commercial litigation
Commitments and contingent liabilities
Amount of claims against entity					$ 140

Subsequent Events (Details)

Subsequent Events (Details) $ in Billions	3 Months Ended
Subsequent Events (Details) $ in Billions	Sep. 30, 2023 USD ($)
Agreement for purchase and licensing of Pfizer's early-stage rare disease gene therapy portfolio \| Forecast \| Maximum \| Licensing rights to Pfizer's early-stage rare disease gene therapy portfolio
Subsequent events
Total consideration	$ 1

H1 2023 - Product Sales year-_3

H1 2023 - Product Sales year-on-year analysis (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2023		Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Product sales
Product Sales	$ 10,882	[1]	$ 10,630	$ 21,448	$ 21,610
Actual %, year-on-year	2%			(1.00%)
CER %, year-on-year	5%			3%
Emerging Markets
Product sales
Product Sales	$ 2,910			$ 6,056
Actual %, year-on-year	5%
CER %, year-on-year	12%			7%
US
Product sales
Product Sales	$ 4,525			$ 8,598
Actual %, year-on-year	7%			4%
Europe
Product sales
Product Sales	$ 2,141			$ 4,257
Actual %, year-on-year	4%			3%
CER %, year-on-year	4%			6%
Established ROW
Product sales
Product Sales	$ 1,306			$ 2,537
Actual %, year-on-year	(16.00%)			(19.00%)
CER %, year-on-year	(9.00%)			(11.00%)
Total Oncology
Product sales
Product Sales	$ 4,382			$ 8,302
Actual %, year-on-year	18%			17%
CER %, year-on-year	22%			21%
Total Oncology \| Emerging Markets
Product sales
Product Sales	$ 987			$ 1,953
Actual %, year-on-year	10%			9%
CER %, year-on-year	18%			17%
Total Oncology \| US
Product sales
Product Sales	$ 1,962			$ 3,666
Actual %, year-on-year	22%			23%
Total Oncology \| Europe
Product sales
Product Sales	$ 819			$ 1,579
Actual %, year-on-year	19%			18%
CER %, year-on-year	19%			21%
Total Oncology \| Established ROW
Product sales
Product Sales	$ 614			$ 1,104
Actual %, year-on-year	21%			13%
CER %, year-on-year	30%			25%
Tagrisso
Product sales
Product Sales	$ 1,491			$ 2,915
Actual %, year-on-year	7%			8%
CER %, year-on-year	10%			12%
Tagrisso \| Emerging Markets
Product sales
Product Sales	$ 408			$ 851
Actual %, year-on-year	2%			6%
CER %, year-on-year	9%			13%
Tagrisso \| US
Product sales
Product Sales	$ 581			$ 1,102
Actual %, year-on-year	13%			16%
Tagrisso \| Europe
Product sales
Product Sales	$ 284			$ 541
Actual %, year-on-year	11%			6%
CER %, year-on-year	11%			9%
Tagrisso \| Established ROW
Product sales
Product Sales	$ 218			$ 421
Actual %, year-on-year	(6.00%)			(4.00%)
CER %, year-on-year	2%			6%
Imfinzi
Product sales
Product Sales	$ 1,076			$ 1,976
Actual %, year-on-year	55%			53%
CER %, year-on-year	58%			57%
Imfinzi \| Emerging Markets
Product sales
Product Sales	$ 102			$ 183
Actual %, year-on-year	35%			37%
CER %, year-on-year	47%			47%
Imfinzi \| US
Product sales
Product Sales	$ 576			$ 1,098
Actual %, year-on-year	54%			60%
Imfinzi \| Europe
Product sales
Product Sales	$ 176			$ 339
Actual %, year-on-year	23%			27%
CER %, year-on-year	23%			30%
Imfinzi \| Established ROW
Product sales
Product Sales	$ 222			$ 356
Actual %, year-on-year				74%
CER %, year-on-year				92%
Lynparza
Product sales
Product Sales	$ 717			$ 1,368
Actual %, year-on-year	7%			6%
CER %, year-on-year	9%			10%
Lynparza \| Emerging Markets
Product sales
Product Sales	$ 142			$ 278
Actual %, year-on-year	18%			15%
CER %, year-on-year	28%			23%
Lynparza \| US
Product sales
Product Sales	$ 311			$ 580
Lynparza \| Europe
Product sales
Product Sales	$ 187			$ 365
Actual %, year-on-year	10%			11%
CER %, year-on-year	11%			14%
Lynparza \| Established ROW
Product sales
Product Sales	$ 77			$ 145
Actual %, year-on-year	7%			5%
CER %, year-on-year	15%			15%
Calquence
Product sales
Product Sales	$ 653			$ 1,185
Actual %, year-on-year	34%			31%
CER %, year-on-year	34%			33%
Calquence \| Emerging Markets
Product sales
Product Sales	$ 24			$ 41
Calquence \| US
Product sales
Product Sales	$ 485			$ 869
Actual %, year-on-year	22%			18%
Calquence \| Europe
Product sales
Product Sales	$ 117			$ 225
Actual %, year-on-year	76%			85%
CER %, year-on-year	78%			92%
Calquence \| Established ROW
Product sales
Product Sales	$ 27			$ 50
Actual %, year-on-year	55%			64%
CER %, year-on-year	64%			75%
Enhertu
Product sales
Product Sales	$ 67			$ 104
Enhertu \| Emerging Markets
Product sales
Product Sales	48			72
Enhertu \| Europe
Product sales
Product Sales	14			24
Enhertu \| Established ROW
Product sales
Product Sales	5			8
Orpathys
Product sales
Product Sales	$ 13			$ 22
Actual %, year-on-year	22%			(7.00%)
CER %, year-on-year	30%
Orpathys \| Emerging Markets
Product sales
Product Sales	$ 13			$ 22
Actual %, year-on-year	22%			(7.00%)
CER %, year-on-year	30%
Zoladex
Product sales
Product Sales	$ 233			$ 459
Actual %, year-on-year	(1.00%)			(4.00%)
CER %, year-on-year	5%			4%
Zoladex \| Emerging Markets
Product sales
Product Sales	$ 171			$ 339
Actual %, year-on-year	4%			2%
CER %, year-on-year	13%			11%
Zoladex \| US
Product sales
Product Sales	$ 4			$ 6
Actual %, year-on-year	25%			(3.00%)
Zoladex \| Europe
Product sales
Product Sales	$ 34			$ 66
Actual %, year-on-year	(1.00%)			(3.00%)
CER %, year-on-year	1%			1%
Zoladex \| Established ROW
Product sales
Product Sales	$ 24			$ 48
Actual %, year-on-year	(31.00%)			(32.00%)
CER %, year-on-year	(26.00%)			(24.00%)
Faslodex
Product sales
Product Sales	$ 78			$ 153
Actual %, year-on-year	(8.00%)			(14.00%)
CER %, year-on-year	(3.00%)			(7.00%)
Faslodex \| Emerging Markets
Product sales
Product Sales	$ 43			$ 81
Actual %, year-on-year	16%
CER %, year-on-year	23%			7%
Faslodex \| US
Product sales
Product Sales	$ 3			$ 7
Actual %, year-on-year	(41.00%)			(37.00%)
Faslodex \| Europe
Product sales
Product Sales	$ 6			$ 16
Actual %, year-on-year	(61.00%)			(50.00%)
CER %, year-on-year	(62.00%)			(48.00%)
Faslodex \| Established ROW
Product sales
Product Sales	$ 26			$ 49
Actual %, year-on-year	(6.00%)			(10.00%)
CER %, year-on-year	1%			1%
Oncology, Others
Product sales
Product Sales	$ 54			$ 120
Actual %, year-on-year	(42.00%)			(37.00%)
CER %, year-on-year	(39.00%)			(33.00%)
Oncology, Others \| Emerging Markets
Product sales
Product Sales	$ 36			$ 86
Actual %, year-on-year	(48.00%)			(39.00%)
CER %, year-on-year	(44.00%)			(35.00%)
Oncology, Others \| US
Product sales
Product Sales	$ 2			$ 4
Actual %, year-on-year	(24.00%)			(26.00%)
Oncology, Others \| Europe
Product sales
Product Sales	$ 1			$ 3
Actual %, year-on-year	(50.00%)			(53.00%)
CER %, year-on-year	(51.00%)			(51.00%)
Oncology, Others \| Established ROW
Product sales
Product Sales	$ 15			$ 27
Actual %, year-on-year	(24.00%)			(28.00%)
CER %, year-on-year	(21.00%)			(22.00%)
BioPharmaceuticals: total CVRM
Product sales
Product Sales	$ 2,675			$ 5,205
Actual %, year-on-year	14%			14%
CER %, year-on-year	18%			19%
BioPharmaceuticals: total CVRM \| Emerging Markets
Product sales
Product Sales	$ 1,182			$ 2,347
Actual %, year-on-year	10%			12%
CER %, year-on-year	18%			20%
BioPharmaceuticals: total CVRM \| US
Product sales
Product Sales	$ 661			$ 1,283
Actual %, year-on-year	5%			11%
BioPharmaceuticals: total CVRM \| Europe
Product sales
Product Sales	$ 611			$ 1,168
Actual %, year-on-year	32%			24%
CER %, year-on-year	33%			27%
BioPharmaceuticals: total CVRM \| Established ROW
Product sales
Product Sales	$ 221			$ 407
Actual %, year-on-year	19%			12%
CER %, year-on-year	27%			23%
Farxiga
Product sales
Product Sales	$ 1,505			$ 2,804
Actual %, year-on-year	36%			33%
CER %, year-on-year	41%			39%
Farxiga \| Emerging Markets
Product sales
Product Sales	$ 576			$ 1,074
Actual %, year-on-year	36%			32%
CER %, year-on-year	45%			41%
Farxiga \| US
Product sales
Product Sales	$ 339			$ 634
Actual %, year-on-year	23%			35%
Farxiga \| Europe
Product sales
Product Sales	$ 456			$ 850
Actual %, year-on-year	48%			36%
CER %, year-on-year	48%			40%
Farxiga \| Established ROW
Product sales
Product Sales	$ 134			$ 246
Actual %, year-on-year	39%			27%
CER %, year-on-year	50%			39%
Brilinta
Product sales
Product Sales	$ 331			$ 665
Actual %, year-on-year	(5.00%)			(1.00%)
CER %, year-on-year	(3.00%)			1%
Brilinta \| Emerging Markets
Product sales
Product Sales	$ 79			$ 160
Actual %, year-on-year	1%			10%
CER %, year-on-year	10%			17%
Brilinta \| US
Product sales
Product Sales	$ 178			$ 357
Actual %, year-on-year	(4.00%)			2%
Brilinta \| Europe
Product sales
Product Sales	$ 68			$ 136
Actual %, year-on-year	(7.00%)			(9.00%)
CER %, year-on-year	(7.00%)			(7.00%)
Brilinta \| Established ROW
Product sales
Product Sales	$ 6			$ 12
Actual %, year-on-year	(55.00%)			(57.00%)
CER %, year-on-year	(53.00%)			(53.00%)
Lokelma
Product sales
Product Sales	$ 100			$ 198
Actual %, year-on-year	51%			53%
CER %, year-on-year	55%			59%
Lokelma \| Emerging Markets
Product sales
Product Sales	$ 13			$ 24
Lokelma \| US
Product sales
Product Sales	$ 49			$ 105
Actual %, year-on-year	26%			35%
Lokelma \| Europe
Product sales
Product Sales	$ 14			$ 25
Actual %, year-on-year	98%			98%
Lokelma \| Established ROW
Product sales
Product Sales	$ 24			$ 44
Actual %, year-on-year	34%			32%
CER %, year-on-year	44%			47%
Roxadustat
Product sales
Product Sales	$ 73			$ 134
Actual %, year-on-year	46%			48%
CER %, year-on-year	56%			59%
Roxadustat \| Emerging Markets
Product sales
Product Sales	$ 73			$ 134
Actual %, year-on-year	46%			48%
CER %, year-on-year	56%			59%
Andexxa
Product sales
Product Sales	$ 45			$ 89
Actual %, year-on-year	23%			28%
CER %, year-on-year	26%			33%
Andexxa \| US
Product sales
Product Sales	$ 16			$ 37
Actual %, year-on-year	(10.00%)			(12.00%)
Andexxa \| Europe
Product sales
Product Sales	$ 15			$ 29
Actual %, year-on-year	70%			64%
CER %, year-on-year	74%			70%
Andexxa \| Established ROW
Product sales
Product Sales	$ 14			$ 23
Actual %, year-on-year	44%
CER %, year-on-year	49%
Crestor.
Product sales
Product Sales	$ 280			$ 585
Actual %, year-on-year				7%
CER %, year-on-year	5%			14%
Crestor. \| Emerging Markets
Product sales
Product Sales	$ 217			$ 458
Actual %, year-on-year				11%
CER %, year-on-year	6%			18%
Crestor. \| US
Product sales
Product Sales	$ 12			$ 26
Actual %, year-on-year	(25.00%)			(23.00%)
Crestor. \| Europe
Product sales
Product Sales	$ 16			$ 32
Actual %, year-on-year	56%			52%
CER %, year-on-year	51%			54%
Crestor. \| Established ROW
Product sales
Product Sales	$ 35			$ 69
Actual %, year-on-year	(4.00%)			(11.00%)
CER %, year-on-year	2%			(3.00%)
Seloken/Toprol-XL
Product sales
Product Sales	$ 164			$ 343
Actual %, year-on-year	(26.00%)			(27.00%)
CER %, year-on-year	(21.00%)			(20.00%)
Seloken/Toprol-XL \| Emerging Markets
Product sales
Product Sales	$ 159			$ 333
Actual %, year-on-year	(27.00%)			(27.00%)
CER %, year-on-year	(21.00%)			(21.00%)
Seloken/Toprol-XL \| US
Product sales
Product Sales	$ 1			$ 1
Seloken/Toprol-XL \| Europe
Product sales
Product Sales	$ 2			$ 6
Actual %, year-on-year	(16.00%)			(6.00%)
CER %, year-on-year	(9.00%)			(6.00%)
Seloken/Toprol-XL \| Established ROW
Product sales
Product Sales	$ 2			$ 3
Actual %, year-on-year	(28.00%)			(26.00%)
CER %, year-on-year	(2.00%)			(11.00%)
Onglyza
Product sales
Product Sales	$ 65			$ 127
Actual %, year-on-year	(9.00%)			(8.00%)
CER %, year-on-year	(6.00%)			(4.00%)
Onglyza \| Emerging Markets
Product sales
Product Sales	$ 30			$ 67
Actual %, year-on-year	(7.00%)			1%
CER %, year-on-year				9%
Onglyza \| US
Product sales
Product Sales	$ 22			$ 36
Actual %, year-on-year	1%			(11.00%)
Onglyza \| Europe
Product sales
Product Sales	$ 8			$ 16
Actual %, year-on-year	(24.00%)			(21.00%)
CER %, year-on-year	(18.00%)			(18.00%)
Onglyza \| Established ROW
Product sales
Product Sales	$ 5			$ 8
Actual %, year-on-year	(30.00%)			(31.00%)
CER %, year-on-year	(37.00%)			(28.00%)
Bydureon
Product sales
Product Sales	$ 43			$ 89
Actual %, year-on-year	(41.00%)			(37.00%)
CER %, year-on-year	(41.00%)			(37.00%)
Bydureon \| Emerging Markets
Product sales
Product Sales	$ 1			$ 2
Actual %, year-on-year	(33.00%)			(1.00%)
CER %, year-on-year	(32.00%)
Bydureon \| US
Product sales
Product Sales	$ 35			$ 73
Actual %, year-on-year	(43.00%)			(38.00%)
Bydureon \| Europe
Product sales
Product Sales	$ 7			$ 14
Actual %, year-on-year	(25.00%)			(32.00%)
CER %, year-on-year	(25.00%)			(30.00%)
CVRM, Others
Product sales
Product Sales	$ 69			$ 171
Actual %, year-on-year	(30.00%)			(13.00%)
CER %, year-on-year	(28.00%)			(10.00%)
CVRM, Others \| Emerging Markets
Product sales
Product Sales	$ 34			$ 95
Actual %, year-on-year	(35.00%)			(9.00%)
CER %, year-on-year	(31.00%)			(3.00%)
CVRM, Others \| US
Product sales
Product Sales	$ 9			$ 14
Actual %, year-on-year	(26.00%)			(26.00%)
CVRM, Others \| Europe
Product sales
Product Sales	$ 25			$ 60
Actual %, year-on-year	(23.00%)			(13.00%)
CER %, year-on-year	(23.00%)			(13.00%)
CVRM, Others \| Established ROW
Product sales
Product Sales	$ 1			$ 2
Actual %, year-on-year	(50.00%)			(57.00%)
CER %, year-on-year	(46.00%)			(53.00%)
BioPharmaceuticals: total Respiratory & Immunology
Product sales
Product Sales	$ 1,483			$ 3,066
Actual %, year-on-year	7%			6%
CER %, year-on-year	10%			10%
BioPharmaceuticals: total Respiratory & Immunology \| Emerging Markets
Product sales
Product Sales	$ 360			$ 893
Actual %, year-on-year	22%			22%
CER %, year-on-year	31%			31%
BioPharmaceuticals: total Respiratory & Immunology \| US
Product sales
Product Sales	$ 674			$ 1,291
Actual %, year-on-year	3%			(1.00%)
BioPharmaceuticals: total Respiratory & Immunology \| Europe
Product sales
Product Sales	$ 289			$ 581
Actual %, year-on-year	6%			6%
CER %, year-on-year	6%			9%
BioPharmaceuticals: total Respiratory & Immunology \| Established ROW
Product sales
Product Sales	$ 160			$ 301
Actual %, year-on-year	1%			(3.00%)
CER %, year-on-year	8%			6%
Symbicort
Product sales
Product Sales	$ 600			$ 1,288
Actual %, year-on-year	(2.00%)
CER %, year-on-year	1%			4%
Symbicort \| Emerging Markets
Product sales
Product Sales	$ 177			$ 405
Actual %, year-on-year	27%			32%
CER %, year-on-year	37%			43%
Symbicort \| US
Product sales
Product Sales	$ 200			$ 434
Actual %, year-on-year	(10.00%)			(10.00%)
Symbicort \| Europe
Product sales
Product Sales	$ 137			$ 284
Actual %, year-on-year	(11.00%)			(9.00%)
CER %, year-on-year	(11.00%)			(6.00%)
Symbicort \| Established ROW
Product sales
Product Sales	$ 86			$ 165
Actual %, year-on-year	(12.00%)			(13.00%)
CER %, year-on-year	(5.00%)			(6.00%)
Fasenra
Product sales
Product Sales	$ 406			$ 744
Actual %, year-on-year	15%			12%
CER %, year-on-year	16%			14%
Fasenra \| Emerging Markets
Product sales
Product Sales	$ 14			$ 29
Actual %, year-on-year	37%			66%
CER %, year-on-year	42%			70%
Fasenra \| US
Product sales
Product Sales	$ 267			$ 468
Actual %, year-on-year	16%			12%
Fasenra \| Europe
Product sales
Product Sales	$ 89			$ 176
Actual %, year-on-year	14%			15%
CER %, year-on-year	14%			19%
Fasenra \| Established ROW
Product sales
Product Sales	$ 36			$ 71
Actual %, year-on-year				(2.00%)
CER %, year-on-year	8%			7%
Breztri
Product sales
Product Sales	$ 163			$ 307
Actual %, year-on-year	75%			71%
CER %, year-on-year	79%			76%
Breztri \| Emerging Markets
Product sales
Product Sales	$ 43			$ 81
Actual %, year-on-year				88%
Breztri \| US
Product sales
Product Sales	$ 84			$ 165
Actual %, year-on-year	57%			55%
Breztri \| Europe
Product sales
Product Sales	$ 21			$ 36
Breztri \| Established ROW
Product sales
Product Sales	$ 15			$ 25
Actual %, year-on-year	54%			53%
CER %, year-on-year	60%			65%
Saphnelo
Product sales
Product Sales	$ 68			$ 115
Saphnelo \| Emerging Markets
Product sales
Product Sales	1			1
Saphnelo \| US
Product sales
Product Sales	64			107
Saphnelo \| Europe
Product sales
Product Sales	1			3
Saphnelo \| Established ROW
Product sales
Product Sales	2			4
Tezspire
Product sales
Product Sales	19			30
Tezspire \| Europe
Product sales
Product Sales	11			17
Tezspire \| Established ROW
Product sales
Product Sales	8			13
Pulmicort
Product sales
Product Sales	$ 124			$ 346
Actual %, year-on-year	7%			4%
CER %, year-on-year	13%			11%
Pulmicort \| Emerging Markets
Product sales
Product Sales	$ 90			$ 273
Actual %, year-on-year	26%			16%
CER %, year-on-year	36%			24%
Pulmicort \| US
Product sales
Product Sales	$ 7			$ 17
Actual %, year-on-year	(53.00%)			(54.00%)
Pulmicort \| Europe
Product sales
Product Sales	$ 16			$ 36
Actual %, year-on-year	(7.00%)			2%
CER %, year-on-year	(7.00%)			6%
Pulmicort \| Established ROW
Product sales
Product Sales	$ 11			$ 20
Actual %, year-on-year	(14.00%)			(23.00%)
CER %, year-on-year	(8.00%)			(17.00%)
Bevespi
Product sales
Product Sales	$ 15			$ 29
Actual %, year-on-year	(1.00%)			(1.00%)
CER %, year-on-year	(3.00%)			(1.00%)
Bevespi \| Emerging Markets
Product sales
Product Sales	$ 2			$ 3
Actual %, year-on-year	76%			36%
CER %, year-on-year	90%			48%
Bevespi \| US
Product sales
Product Sales	$ 8			$ 17
Actual %, year-on-year	(30.00%)			(23.00%)
Bevespi \| Europe
Product sales
Product Sales	$ 5			$ 9
Actual %, year-on-year	77%			67%
CER %, year-on-year	73%			69%
Daliresp/Daxas
Product sales
Product Sales	$ 17			$ 30
Actual %, year-on-year	(71.00%)			(72.00%)
CER %, year-on-year	(70.00%)			(72.00%)
Daliresp/Daxas \| Emerging Markets
Product sales
Product Sales	$ 1			$ 1
Actual %, year-on-year	(13.00%)			(16.00%)
CER %, year-on-year	(10.00%)			(14.00%)
Daliresp/Daxas \| US
Product sales
Product Sales	$ 14			$ 24
Actual %, year-on-year	(74.00%)			(77.00%)
Daliresp/Daxas \| Europe
Product sales
Product Sales	$ 2			$ 5
Actual %, year-on-year	(15.00%)			(11.00%)
CER %, year-on-year	(8.00%)			(5.00%)
Daliresp/Daxas \| Established ROW
Product sales
Actual %, year-on-year				(39.00%)
CER %, year-on-year				(36.00%)
Respiratory, Others
Product sales
Product Sales	$ 71			$ 177
Actual %, year-on-year	(34.00%)			(30.00%)
CER %, year-on-year	(32.00%)			(26.00%)
Respiratory, Others \| Emerging Markets
Product sales
Product Sales	$ 32			$ 100
Actual %, year-on-year	(36.00%)			(20.00%)
CER %, year-on-year	(32.00%)			(13.00%)
Respiratory, Others \| US
Product sales
Product Sales	$ 30			$ 59
Actual %, year-on-year	(35.00%)			(40.00%)
Respiratory, Others \| Europe
Product sales
Product Sales	$ 7			$ 15
Actual %, year-on-year	(20.00%)			(42.00%)
CER %, year-on-year	(18.00%)			(39.00%)
Respiratory, Others \| Established ROW
Product sales
Product Sales	$ 2			$ 3
Actual %, year-on-year	6%			(3.00%)
CER %, year-on-year	5%
BioPharmaceuticals: Total V&I
Product sales
Product Sales	$ 88			$ 443
Actual %, year-on-year	(91.00%)			(84.00%)
CER %, year-on-year	(90.00%)			(83.00%)
BioPharmaceuticals: Total V&I \| Emerging Markets
Product sales
Product Sales	$ 46			$ 149
Actual %, year-on-year	(80.00%)			(83.00%)
CER %, year-on-year	(78.00%)			(82.00%)
BioPharmaceuticals: Total V&I \| Europe
Product sales
Product Sales	$ 15			$ 114
Actual %, year-on-year	(93.00%)			(78.00%)
CER %, year-on-year	(93.00%)			(77.00%)
BioPharmaceuticals: Total V&I \| Established ROW
Product sales
Product Sales	$ 27			$ 180
Actual %, year-on-year	(90.00%)			(75.00%)
CER %, year-on-year	(89.00%)			(72.00%)
Covid-19 mAbs [Member]
Product sales
Product Sales				$ 126
Actual %, year-on-year				(86.00%)
CER %, year-on-year				(85.00%)
Covid-19 mAbs [Member] \| Emerging Markets
Product sales
Product Sales				$ 5
Actual %, year-on-year				(95.00%)
CER %, year-on-year				(95.00%)
Covid-19 mAbs [Member] \| Europe
Product sales
Product Sales	$ 3			$ 7
Actual %, year-on-year	(96.00%)			(95.00%)
CER %, year-on-year	(97.00%)			(95.00%)
Covid-19 mAbs [Member] \| Established ROW
Product sales
Product Sales				$ 114
Actual %, year-on-year				(6.00%)
CER %, year-on-year				6%
Vaxzevria
Product sales
Product Sales				$ 28
Actual %, year-on-year				(98.00%)
CER %, year-on-year				(98.00%)
Vaxzevria \| Emerging Markets
Product sales
Product Sales				$ 18
Actual %, year-on-year				(97.00%)
CER %, year-on-year				(97.00%)
Vaxzevria \| Europe
Product sales
Product Sales				$ 10
Actual %, year-on-year				(96.00%)
CER %, year-on-year				(96.00%)
Beyfortus [Member]
Product sales
Product Sales	$ 2			$ 2
Beyfortus [Member] \| Europe
Product sales
Product Sales	2			2
Synagis
Product sales
Product Sales	$ 87			$ 284
Actual %, year-on-year	8%			1%
CER %, year-on-year	16%			8%
Synagis \| Emerging Markets
Product sales
Product Sales	$ 49			$ 126
Actual %, year-on-year	16%			17%
CER %, year-on-year	27%			23%
Synagis \| Europe
Product sales
Product Sales	$ 10			$ 92
Actual %, year-on-year	(48.00%)			(13.00%)
CER %, year-on-year	(47.00%)			(9.00%)
Synagis \| Established ROW
Product sales
Product Sales	$ 28			$ 66
Actual %, year-on-year	63%			3%
CER %, year-on-year	75%			15%
FluMist
Product sales
Product Sales				$ 3
FluMist \| Europe
Product sales
Product Sales				3
Total rare diseases
Product sales
Product Sales	$ 1,953			$ 3,819
Actual %, year-on-year	8%			9%
CER %, year-on-year	10%			12%
Total rare diseases \| Emerging Markets
Product sales
Product Sales	$ 150			$ 324
Actual %, year-on-year	65%			57%
CER %, year-on-year	78%			67%
Total rare diseases \| US
Product sales
Product Sales	$ 1,196			$ 2,290
Actual %, year-on-year	12%			10%
Total rare diseases \| Europe
Product sales
Product Sales	$ 381			$ 767
Actual %, year-on-year	2%			5%
CER %, year-on-year	2%			8%
Total rare diseases \| Established ROW
Product sales
Product Sales	$ 226			$ 438
Actual %, year-on-year	(15.00%)			(6.00%)
CER %, year-on-year	(9.00%)			4%
Soliris
Product sales
Product Sales	$ 814			$ 1,648
Actual %, year-on-year	(21.00%)			(18.00%)
CER %, year-on-year	(19.00%)			(16.00%)
Soliris \| Emerging Markets
Product sales
Product Sales	$ 99			$ 214
Actual %, year-on-year	57%			60%
CER %, year-on-year	74%			76%
Soliris \| US
Product sales
Product Sales	$ 445			$ 893
Actual %, year-on-year	(23.00%)			(23.00%)
Soliris \| Europe
Product sales
Product Sales	$ 184			$ 367
Actual %, year-on-year	(15.00%)			(16.00%)
CER %, year-on-year	(15.00%)			(14.00%)
Soliris \| Established ROW
Product sales
Product Sales	$ 86			$ 174
Actual %, year-on-year	(50.00%)			(38.00%)
CER %, year-on-year	(47.00%)			(33.00%)
Ultomiris
Product sales
Product Sales	$ 713			$ 1,364
Actual %, year-on-year	64%			60%
CER %, year-on-year	66%			64%
Ultomiris \| Emerging Markets
Product sales
Product Sales	$ 17			$ 30
CER %, year-on-year				2%
Ultomiris \| US
Product sales
Product Sales	$ 434			$ 815
Actual %, year-on-year	84%			79%
Ultomiris \| Europe
Product sales
Product Sales	$ 152			$ 311
Actual %, year-on-year	26%			38%
CER %, year-on-year	26%			42%
Ultomiris \| Established ROW
Product sales
Product Sales	$ 110			$ 208
Actual %, year-on-year	53%			46%
CER %, year-on-year	64%			62%
Strensiq
Product sales
Product Sales	$ 300			$ 562
Actual %, year-on-year	24%			25%
CER %, year-on-year	25%			26%
Strensiq \| Emerging Markets
Product sales
Product Sales	$ 9			$ 24
Actual %, year-on-year	(1.00%)			33%
CER %, year-on-year	(4.00%)			26%
Strensiq \| US
Product sales
Product Sales	$ 248			$ 453
Actual %, year-on-year	29%			28%
Strensiq \| Europe
Product sales
Product Sales	$ 21			$ 42
Actual %, year-on-year				5%
CER %, year-on-year	(1.00%)			8%
Strensiq \| Established ROW
Product sales
Product Sales	$ 22			$ 43
Actual %, year-on-year	16%			12%
CER %, year-on-year	25%			23%
Koselugo
Product sales
Product Sales	$ 80			$ 159
Actual %, year-on-year	28%			57%
CER %, year-on-year	30%			57%
Koselugo \| Emerging Markets
Product sales
Product Sales	$ 14			$ 38
Actual %, year-on-year	36%
CER %, year-on-year	38%
Koselugo \| US
Product sales
Product Sales	$ 48			$ 89
Actual %, year-on-year	2%			15%
Koselugo \| Europe
Product sales
Product Sales	$ 12			$ 23
Koselugo \| Established ROW
Product sales
Product Sales	6			9
Kanuma
Product sales
Product Sales	$ 46			$ 86
Actual %, year-on-year	28%			16%
CER %, year-on-year	30%			17%
Kanuma \| Emerging Markets
Product sales
Product Sales	$ 11			$ 18
Actual %, year-on-year				95%
CER %, year-on-year				96%
Kanuma \| US
Product sales
Product Sales	$ 21			$ 40
Actual %, year-on-year	5%			4%
Kanuma \| Europe
Product sales
Product Sales	$ 12			$ 24
Actual %, year-on-year	5%			5%
CER %, year-on-year	4%			7%
Kanuma \| Established ROW
Product sales
Product Sales	$ 2			$ 4
Actual %, year-on-year	(4.00%)			12%
CER %, year-on-year	3%			22%
Total Other medicines
Product sales
Product Sales	$ 301			$ 613
Actual %, year-on-year	(28.00%)			(27.00%)
CER %, year-on-year	(24.00%)			(22.00%)
Total Other medicines \| Emerging Markets
Product sales
Product Sales	$ 185			$ 390
Actual %, year-on-year	(3.00%)			(1.00%)
CER %, year-on-year	4%			6%
Total Other medicines \| US
Product sales
Product Sales	$ 32			$ 68
Actual %, year-on-year	(11.00%)			(9.00%)
Total Other medicines \| Europe
Product sales
Product Sales	$ 26			$ 48
Actual %, year-on-year	(16.00%)			(28.00%)
CER %, year-on-year	(17.00%)			(27.00%)
Total Other medicines \| Established ROW
Product sales
Product Sales	$ 58			$ 107
Actual %, year-on-year	(64.00%)			(65.00%)
CER %, year-on-year	(61.00%)			(61.00%)
Nexium
Product sales
Product Sales	$ 248			$ 492
Actual %, year-on-year	(28.00%)			(27.00%)
CER %, year-on-year	(23.00%)			(22.00%)
Nexium \| Emerging Markets
Product sales
Product Sales	$ 149			$ 305
Actual %, year-on-year	3%			6%
CER %, year-on-year	11%			14%
Nexium \| US
Product sales
Product Sales	$ 30			$ 60
Actual %, year-on-year				(6.00%)
Nexium \| Europe
Product sales
Product Sales	$ 14			$ 25
Actual %, year-on-year	16%			(4.00%)
CER %, year-on-year	15%			(2.00%)
Nexium \| Established ROW
Product sales
Product Sales	$ 55			$ 102
Actual %, year-on-year	(65.00%)			(65.00%)
CER %, year-on-year	(62.00%)			(62.00%)
Other, Others
Product sales
Product Sales	$ 53			$ 121
Actual %, year-on-year	(29.00%)			(28.00%)
CER %, year-on-year	(27.00%)			(25.00%)
Other, Others \| Emerging Markets
Product sales
Product Sales	$ 36			$ 85
Actual %, year-on-year	(22.00%)			(20.00%)
CER %, year-on-year	(18.00%)			(15.00%)
Other, Others \| US
Product sales
Product Sales	$ 2			$ 8
Actual %, year-on-year	(68.00%)			(26.00%)
Other, Others \| Europe
Product sales
Product Sales	$ 12			$ 23
Actual %, year-on-year	(36.00%)			(44.00%)
CER %, year-on-year	(36.00%)			(44.00%)
Other, Others \| Established ROW
Product sales
Product Sales	$ 3			$ 5
Actual %, year-on-year	(28.00%)			(49.00%)
CER %, year-on-year	(31.00%)			(47.00%)

[1] The Q2 2023 and Q2 2022 information in respect of the three months ended 30 June 2023 and 30 June 2022 respectively included in the Interim Financial Statements have not been reviewed by PricewaterhouseCoopers LLP.

Q1 2023 Product Sales year-on-y

Q1 2023 Product Sales year-on-year analysis (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2023		Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Product sales
Product Sales	$ 10,882	[1]	$ 10,630	$ 21,448	$ 21,610
Actual %, year-on-year	2%			(1.00%)
CER %, year-on-year	5%			3%
Emerging Markets
Product sales
Product Sales	$ 2,910			$ 6,056
Actual %, year-on-year	5%
CER %, year-on-year	12%			7%
US
Product sales
Product Sales	$ 4,525			$ 8,598
Actual %, year-on-year	7%			4%
Europe
Product sales
Product Sales	$ 2,141			$ 4,257
Actual %, year-on-year	4%			3%
CER %, year-on-year	4%			6%
Established ROW
Product sales
Product Sales	$ 1,306			$ 2,537
Actual %, year-on-year	(16.00%)			(19.00%)
CER %, year-on-year	(9.00%)			(11.00%)
Total Oncology
Product sales
Product Sales	$ 4,382			$ 8,302
Actual %, year-on-year	18%			17%
CER %, year-on-year	22%			21%
Total Oncology \| Emerging Markets
Product sales
Product Sales	$ 987			$ 1,953
Actual %, year-on-year	10%			9%
CER %, year-on-year	18%			17%
Total Oncology \| US
Product sales
Product Sales	$ 1,962			$ 3,666
Actual %, year-on-year	22%			23%
Total Oncology \| Europe
Product sales
Product Sales	$ 819			$ 1,579
Actual %, year-on-year	19%			18%
CER %, year-on-year	19%			21%
Total Oncology \| Established ROW
Product sales
Product Sales	$ 614			$ 1,104
Actual %, year-on-year	21%			13%
CER %, year-on-year	30%			25%
Tagrisso
Product sales
Product Sales	$ 1,491			$ 2,915
Actual %, year-on-year	7%			8%
CER %, year-on-year	10%			12%
Tagrisso \| Emerging Markets
Product sales
Product Sales	$ 408			$ 851
Actual %, year-on-year	2%			6%
CER %, year-on-year	9%			13%
Tagrisso \| US
Product sales
Product Sales	$ 581			$ 1,102
Actual %, year-on-year	13%			16%
Tagrisso \| Europe
Product sales
Product Sales	$ 284			$ 541
Actual %, year-on-year	11%			6%
CER %, year-on-year	11%			9%
Tagrisso \| Established ROW
Product sales
Product Sales	$ 218			$ 421
Actual %, year-on-year	(6.00%)			(4.00%)
CER %, year-on-year	2%			6%
Imfinzi
Product sales
Product Sales	$ 1,076			$ 1,976
Actual %, year-on-year	55%			53%
CER %, year-on-year	58%			57%
Imfinzi \| Emerging Markets
Product sales
Product Sales	$ 102			$ 183
Actual %, year-on-year	35%			37%
CER %, year-on-year	47%			47%
Imfinzi \| US
Product sales
Product Sales	$ 576			$ 1,098
Actual %, year-on-year	54%			60%
Imfinzi \| Europe
Product sales
Product Sales	$ 176			$ 339
Actual %, year-on-year	23%			27%
CER %, year-on-year	23%			30%
Imfinzi \| Established ROW
Product sales
Product Sales	$ 222			$ 356
Actual %, year-on-year				74%
CER %, year-on-year				92%
Lynparza
Product sales
Product Sales	$ 717			$ 1,368
Actual %, year-on-year	7%			6%
CER %, year-on-year	9%			10%
Lynparza \| Emerging Markets
Product sales
Product Sales	$ 142			$ 278
Actual %, year-on-year	18%			15%
CER %, year-on-year	28%			23%
Lynparza \| US
Product sales
Product Sales	$ 311			$ 580
Lynparza \| Europe
Product sales
Product Sales	$ 187			$ 365
Actual %, year-on-year	10%			11%
CER %, year-on-year	11%			14%
Lynparza \| Established ROW
Product sales
Product Sales	$ 77			$ 145
Actual %, year-on-year	7%			5%
CER %, year-on-year	15%			15%
Calquence
Product sales
Product Sales	$ 653			$ 1,185
Actual %, year-on-year	34%			31%
CER %, year-on-year	34%			33%
Calquence \| Emerging Markets
Product sales
Product Sales	$ 24			$ 41
Calquence \| US
Product sales
Product Sales	$ 485			$ 869
Actual %, year-on-year	22%			18%
Calquence \| Europe
Product sales
Product Sales	$ 117			$ 225
Actual %, year-on-year	76%			85%
CER %, year-on-year	78%			92%
Calquence \| Established ROW
Product sales
Product Sales	$ 27			$ 50
Actual %, year-on-year	55%			64%
CER %, year-on-year	64%			75%
Enhertu
Product sales
Product Sales	$ 67			$ 104
Enhertu \| Emerging Markets
Product sales
Product Sales	48			72
Enhertu \| Europe
Product sales
Product Sales	14			24
Enhertu \| Established ROW
Product sales
Product Sales	5			8
Orpathys
Product sales
Product Sales	$ 13			$ 22
Actual %, year-on-year	22%			(7.00%)
CER %, year-on-year	30%
Orpathys \| Emerging Markets
Product sales
Product Sales	$ 13			$ 22
Actual %, year-on-year	22%			(7.00%)
CER %, year-on-year	30%
Zoladex
Product sales
Product Sales	$ 233			$ 459
Actual %, year-on-year	(1.00%)			(4.00%)
CER %, year-on-year	5%			4%
Zoladex \| Emerging Markets
Product sales
Product Sales	$ 171			$ 339
Actual %, year-on-year	4%			2%
CER %, year-on-year	13%			11%
Zoladex \| US
Product sales
Product Sales	$ 4			$ 6
Actual %, year-on-year	25%			(3.00%)
Zoladex \| Europe
Product sales
Product Sales	$ 34			$ 66
Actual %, year-on-year	(1.00%)			(3.00%)
CER %, year-on-year	1%			1%
Zoladex \| Established ROW
Product sales
Product Sales	$ 24			$ 48
Actual %, year-on-year	(31.00%)			(32.00%)
CER %, year-on-year	(26.00%)			(24.00%)
Faslodex
Product sales
Product Sales	$ 78			$ 153
Actual %, year-on-year	(8.00%)			(14.00%)
CER %, year-on-year	(3.00%)			(7.00%)
Faslodex \| Emerging Markets
Product sales
Product Sales	$ 43			$ 81
Actual %, year-on-year	16%
CER %, year-on-year	23%			7%
Faslodex \| US
Product sales
Product Sales	$ 3			$ 7
Actual %, year-on-year	(41.00%)			(37.00%)
Faslodex \| Europe
Product sales
Product Sales	$ 6			$ 16
Actual %, year-on-year	(61.00%)			(50.00%)
CER %, year-on-year	(62.00%)			(48.00%)
Faslodex \| Established ROW
Product sales
Product Sales	$ 26			$ 49
Actual %, year-on-year	(6.00%)			(10.00%)
CER %, year-on-year	1%			1%
Oncology, Others
Product sales
Product Sales	$ 54			$ 120
Actual %, year-on-year	(42.00%)			(37.00%)
CER %, year-on-year	(39.00%)			(33.00%)
Oncology, Others \| Emerging Markets
Product sales
Product Sales	$ 36			$ 86
Actual %, year-on-year	(48.00%)			(39.00%)
CER %, year-on-year	(44.00%)			(35.00%)
Oncology, Others \| US
Product sales
Product Sales	$ 2			$ 4
Actual %, year-on-year	(24.00%)			(26.00%)
Oncology, Others \| Europe
Product sales
Product Sales	$ 1			$ 3
Actual %, year-on-year	(50.00%)			(53.00%)
CER %, year-on-year	(51.00%)			(51.00%)
Oncology, Others \| Established ROW
Product sales
Product Sales	$ 15			$ 27
Actual %, year-on-year	(24.00%)			(28.00%)
CER %, year-on-year	(21.00%)			(22.00%)
BioPharmaceuticals: total CVRM
Product sales
Product Sales	$ 2,675			$ 5,205
Actual %, year-on-year	14%			14%
CER %, year-on-year	18%			19%
BioPharmaceuticals: total CVRM \| Emerging Markets
Product sales
Product Sales	$ 1,182			$ 2,347
Actual %, year-on-year	10%			12%
CER %, year-on-year	18%			20%
BioPharmaceuticals: total CVRM \| US
Product sales
Product Sales	$ 661			$ 1,283
Actual %, year-on-year	5%			11%
BioPharmaceuticals: total CVRM \| Europe
Product sales
Product Sales	$ 611			$ 1,168
Actual %, year-on-year	32%			24%
CER %, year-on-year	33%			27%
BioPharmaceuticals: total CVRM \| Established ROW
Product sales
Product Sales	$ 221			$ 407
Actual %, year-on-year	19%			12%
CER %, year-on-year	27%			23%
Farxiga
Product sales
Product Sales	$ 1,505			$ 2,804
Actual %, year-on-year	36%			33%
CER %, year-on-year	41%			39%
Farxiga \| Emerging Markets
Product sales
Product Sales	$ 576			$ 1,074
Actual %, year-on-year	36%			32%
CER %, year-on-year	45%			41%
Farxiga \| US
Product sales
Product Sales	$ 339			$ 634
Actual %, year-on-year	23%			35%
Farxiga \| Europe
Product sales
Product Sales	$ 456			$ 850
Actual %, year-on-year	48%			36%
CER %, year-on-year	48%			40%
Farxiga \| Established ROW
Product sales
Product Sales	$ 134			$ 246
Actual %, year-on-year	39%			27%
CER %, year-on-year	50%			39%
Brilinta
Product sales
Product Sales	$ 331			$ 665
Actual %, year-on-year	(5.00%)			(1.00%)
CER %, year-on-year	(3.00%)			1%
Brilinta \| Emerging Markets
Product sales
Product Sales	$ 79			$ 160
Actual %, year-on-year	1%			10%
CER %, year-on-year	10%			17%
Brilinta \| US
Product sales
Product Sales	$ 178			$ 357
Actual %, year-on-year	(4.00%)			2%
Brilinta \| Europe
Product sales
Product Sales	$ 68			$ 136
Actual %, year-on-year	(7.00%)			(9.00%)
CER %, year-on-year	(7.00%)			(7.00%)
Brilinta \| Established ROW
Product sales
Product Sales	$ 6			$ 12
Actual %, year-on-year	(55.00%)			(57.00%)
CER %, year-on-year	(53.00%)			(53.00%)
Lokelma
Product sales
Product Sales	$ 100			$ 198
Actual %, year-on-year	51%			53%
CER %, year-on-year	55%			59%
Lokelma \| Emerging Markets
Product sales
Product Sales	$ 13			$ 24
Lokelma \| US
Product sales
Product Sales	$ 49			$ 105
Actual %, year-on-year	26%			35%
Lokelma \| Europe
Product sales
Product Sales	$ 14			$ 25
Actual %, year-on-year	98%			98%
Lokelma \| Established ROW
Product sales
Product Sales	$ 24			$ 44
Actual %, year-on-year	34%			32%
CER %, year-on-year	44%			47%
Roxadustat
Product sales
Product Sales	$ 73			$ 134
Actual %, year-on-year	46%			48%
CER %, year-on-year	56%			59%
Roxadustat \| Emerging Markets
Product sales
Product Sales	$ 73			$ 134
Actual %, year-on-year	46%			48%
CER %, year-on-year	56%			59%
Crestor.
Product sales
Product Sales	$ 280			$ 585
Actual %, year-on-year				7%
CER %, year-on-year	5%			14%
Crestor. \| Emerging Markets
Product sales
Product Sales	$ 217			$ 458
Actual %, year-on-year				11%
CER %, year-on-year	6%			18%
Crestor. \| US
Product sales
Product Sales	$ 12			$ 26
Actual %, year-on-year	(25.00%)			(23.00%)
Crestor. \| Europe
Product sales
Product Sales	$ 16			$ 32
Actual %, year-on-year	56%			52%
CER %, year-on-year	51%			54%
Crestor. \| Established ROW
Product sales
Product Sales	$ 35			$ 69
Actual %, year-on-year	(4.00%)			(11.00%)
CER %, year-on-year	2%			(3.00%)
Seloken/Toprol-XL
Product sales
Product Sales	$ 164			$ 343
Actual %, year-on-year	(26.00%)			(27.00%)
CER %, year-on-year	(21.00%)			(20.00%)
Seloken/Toprol-XL \| Emerging Markets
Product sales
Product Sales	$ 159			$ 333
Actual %, year-on-year	(27.00%)			(27.00%)
CER %, year-on-year	(21.00%)			(21.00%)
Seloken/Toprol-XL \| US
Product sales
Product Sales	$ 1			$ 1
Seloken/Toprol-XL \| Europe
Product sales
Product Sales	$ 2			$ 6
Actual %, year-on-year	(16.00%)			(6.00%)
CER %, year-on-year	(9.00%)			(6.00%)
Seloken/Toprol-XL \| Established ROW
Product sales
Product Sales	$ 2			$ 3
Actual %, year-on-year	(28.00%)			(26.00%)
CER %, year-on-year	(2.00%)			(11.00%)
Onglyza
Product sales
Product Sales	$ 65			$ 127
Actual %, year-on-year	(9.00%)			(8.00%)
CER %, year-on-year	(6.00%)			(4.00%)
Onglyza \| Emerging Markets
Product sales
Product Sales	$ 30			$ 67
Actual %, year-on-year	(7.00%)			1%
CER %, year-on-year				9%
Onglyza \| US
Product sales
Product Sales	$ 22			$ 36
Actual %, year-on-year	1%			(11.00%)
Onglyza \| Europe
Product sales
Product Sales	$ 8			$ 16
Actual %, year-on-year	(24.00%)			(21.00%)
CER %, year-on-year	(18.00%)			(18.00%)
Onglyza \| Established ROW
Product sales
Product Sales	$ 5			$ 8
Actual %, year-on-year	(30.00%)			(31.00%)
CER %, year-on-year	(37.00%)			(28.00%)
Bydureon
Product sales
Product Sales	$ 43			$ 89
Actual %, year-on-year	(41.00%)			(37.00%)
CER %, year-on-year	(41.00%)			(37.00%)
Bydureon \| Emerging Markets
Product sales
Product Sales	$ 1			$ 2
Actual %, year-on-year	(33.00%)			(1.00%)
CER %, year-on-year	(32.00%)
Bydureon \| US
Product sales
Product Sales	$ 35			$ 73
Actual %, year-on-year	(43.00%)			(38.00%)
Bydureon \| Europe
Product sales
Product Sales	$ 7			$ 14
Actual %, year-on-year	(25.00%)			(32.00%)
CER %, year-on-year	(25.00%)			(30.00%)
CVRM, Others
Product sales
Product Sales	$ 69			$ 171
Actual %, year-on-year	(30.00%)			(13.00%)
CER %, year-on-year	(28.00%)			(10.00%)
CVRM, Others \| Emerging Markets
Product sales
Product Sales	$ 34			$ 95
Actual %, year-on-year	(35.00%)			(9.00%)
CER %, year-on-year	(31.00%)			(3.00%)
CVRM, Others \| US
Product sales
Product Sales	$ 9			$ 14
Actual %, year-on-year	(26.00%)			(26.00%)
CVRM, Others \| Europe
Product sales
Product Sales	$ 25			$ 60
Actual %, year-on-year	(23.00%)			(13.00%)
CER %, year-on-year	(23.00%)			(13.00%)
CVRM, Others \| Established ROW
Product sales
Product Sales	$ 1			$ 2
Actual %, year-on-year	(50.00%)			(57.00%)
CER %, year-on-year	(46.00%)			(53.00%)
BioPharmaceuticals: total Respiratory & Immunology
Product sales
Product Sales	$ 1,483			$ 3,066
Actual %, year-on-year	7%			6%
CER %, year-on-year	10%			10%
BioPharmaceuticals: total Respiratory & Immunology \| Emerging Markets
Product sales
Product Sales	$ 360			$ 893
Actual %, year-on-year	22%			22%
CER %, year-on-year	31%			31%
BioPharmaceuticals: total Respiratory & Immunology \| US
Product sales
Product Sales	$ 674			$ 1,291
Actual %, year-on-year	3%			(1.00%)
BioPharmaceuticals: total Respiratory & Immunology \| Europe
Product sales
Product Sales	$ 289			$ 581
Actual %, year-on-year	6%			6%
CER %, year-on-year	6%			9%
BioPharmaceuticals: total Respiratory & Immunology \| Established ROW
Product sales
Product Sales	$ 160			$ 301
Actual %, year-on-year	1%			(3.00%)
CER %, year-on-year	8%			6%
Symbicort
Product sales
Product Sales	$ 600			$ 1,288
Actual %, year-on-year	(2.00%)
CER %, year-on-year	1%			4%
Symbicort \| Emerging Markets
Product sales
Product Sales	$ 177			$ 405
Actual %, year-on-year	27%			32%
CER %, year-on-year	37%			43%
Symbicort \| US
Product sales
Product Sales	$ 200			$ 434
Actual %, year-on-year	(10.00%)			(10.00%)
Symbicort \| Europe
Product sales
Product Sales	$ 137			$ 284
Actual %, year-on-year	(11.00%)			(9.00%)
CER %, year-on-year	(11.00%)			(6.00%)
Symbicort \| Established ROW
Product sales
Product Sales	$ 86			$ 165
Actual %, year-on-year	(12.00%)			(13.00%)
CER %, year-on-year	(5.00%)			(6.00%)
Fasenra
Product sales
Product Sales	$ 406			$ 744
Actual %, year-on-year	15%			12%
CER %, year-on-year	16%			14%
Fasenra \| Emerging Markets
Product sales
Product Sales	$ 14			$ 29
Actual %, year-on-year	37%			66%
CER %, year-on-year	42%			70%
Fasenra \| US
Product sales
Product Sales	$ 267			$ 468
Actual %, year-on-year	16%			12%
Fasenra \| Europe
Product sales
Product Sales	$ 89			$ 176
Actual %, year-on-year	14%			15%
CER %, year-on-year	14%			19%
Fasenra \| Established ROW
Product sales
Product Sales	$ 36			$ 71
Actual %, year-on-year				(2.00%)
CER %, year-on-year	8%			7%
Breztri
Product sales
Product Sales	$ 163			$ 307
Actual %, year-on-year	75%			71%
CER %, year-on-year	79%			76%
Breztri \| Emerging Markets
Product sales
Product Sales	$ 43			$ 81
Actual %, year-on-year				88%
Breztri \| US
Product sales
Product Sales	$ 84			$ 165
Actual %, year-on-year	57%			55%
Breztri \| Europe
Product sales
Product Sales	$ 21			$ 36
Breztri \| Established ROW
Product sales
Product Sales	$ 15			$ 25
Actual %, year-on-year	54%			53%
CER %, year-on-year	60%			65%
Saphnelo
Product sales
Product Sales	$ 68			$ 115
Saphnelo \| Emerging Markets
Product sales
Product Sales	1			1
Saphnelo \| US
Product sales
Product Sales	64			107
Saphnelo \| Europe
Product sales
Product Sales	1			3
Saphnelo \| Established ROW
Product sales
Product Sales	2			4
Tezspire
Product sales
Product Sales	19			30
Tezspire \| Europe
Product sales
Product Sales	11			17
Tezspire \| Established ROW
Product sales
Product Sales	8			13
Pulmicort
Product sales
Product Sales	$ 124			$ 346
Actual %, year-on-year	7%			4%
CER %, year-on-year	13%			11%
Pulmicort \| Emerging Markets
Product sales
Product Sales	$ 90			$ 273
Actual %, year-on-year	26%			16%
CER %, year-on-year	36%			24%
Pulmicort \| US
Product sales
Product Sales	$ 7			$ 17
Actual %, year-on-year	(53.00%)			(54.00%)
Pulmicort \| Europe
Product sales
Product Sales	$ 16			$ 36
Actual %, year-on-year	(7.00%)			2%
CER %, year-on-year	(7.00%)			6%
Pulmicort \| Established ROW
Product sales
Product Sales	$ 11			$ 20
Actual %, year-on-year	(14.00%)			(23.00%)
CER %, year-on-year	(8.00%)			(17.00%)
Bevespi
Product sales
Product Sales	$ 15			$ 29
Actual %, year-on-year	(1.00%)			(1.00%)
CER %, year-on-year	(3.00%)			(1.00%)
Bevespi \| Emerging Markets
Product sales
Product Sales	$ 2			$ 3
Actual %, year-on-year	76%			36%
CER %, year-on-year	90%			48%
Bevespi \| US
Product sales
Product Sales	$ 8			$ 17
Actual %, year-on-year	(30.00%)			(23.00%)
Bevespi \| Europe
Product sales
Product Sales	$ 5			$ 9
Actual %, year-on-year	77%			67%
CER %, year-on-year	73%			69%
Daliresp/Daxas
Product sales
Product Sales	$ 17			$ 30
Actual %, year-on-year	(71.00%)			(72.00%)
CER %, year-on-year	(70.00%)			(72.00%)
Daliresp/Daxas \| Emerging Markets
Product sales
Product Sales	$ 1			$ 1
Actual %, year-on-year	(13.00%)			(16.00%)
CER %, year-on-year	(10.00%)			(14.00%)
Daliresp/Daxas \| US
Product sales
Product Sales	$ 14			$ 24
Actual %, year-on-year	(74.00%)			(77.00%)
Daliresp/Daxas \| Europe
Product sales
Product Sales	$ 2			$ 5
Actual %, year-on-year	(15.00%)			(11.00%)
CER %, year-on-year	(8.00%)			(5.00%)
Daliresp/Daxas \| Established ROW
Product sales
Actual %, year-on-year				(39.00%)
CER %, year-on-year				(36.00%)
Respiratory, Others
Product sales
Product Sales	$ 71			$ 177
Actual %, year-on-year	(34.00%)			(30.00%)
CER %, year-on-year	(32.00%)			(26.00%)
Respiratory, Others \| Emerging Markets
Product sales
Product Sales	$ 32			$ 100
Actual %, year-on-year	(36.00%)			(20.00%)
CER %, year-on-year	(32.00%)			(13.00%)
Respiratory, Others \| US
Product sales
Product Sales	$ 30			$ 59
Actual %, year-on-year	(35.00%)			(40.00%)
Respiratory, Others \| Europe
Product sales
Product Sales	$ 7			$ 15
Actual %, year-on-year	(20.00%)			(42.00%)
CER %, year-on-year	(18.00%)			(39.00%)
Respiratory, Others \| Established ROW
Product sales
Product Sales	$ 2			$ 3
Actual %, year-on-year	6%			(3.00%)
CER %, year-on-year	5%
BioPharmaceuticals: Total V&I
Product sales
Product Sales	$ 88			$ 443
Actual %, year-on-year	(91.00%)			(84.00%)
CER %, year-on-year	(90.00%)			(83.00%)
BioPharmaceuticals: Total V&I \| Emerging Markets
Product sales
Product Sales	$ 46			$ 149
Actual %, year-on-year	(80.00%)			(83.00%)
CER %, year-on-year	(78.00%)			(82.00%)
BioPharmaceuticals: Total V&I \| Europe
Product sales
Product Sales	$ 15			$ 114
Actual %, year-on-year	(93.00%)			(78.00%)
CER %, year-on-year	(93.00%)			(77.00%)
BioPharmaceuticals: Total V&I \| Established ROW
Product sales
Product Sales	$ 27			$ 180
Actual %, year-on-year	(90.00%)			(75.00%)
CER %, year-on-year	(89.00%)			(72.00%)
Covid-19 mAbs
Product sales
Product Sales				$ 126
Product sales net of reversals	$ (1)
Actual %, year-on-year				(86.00%)
CER %, year-on-year				(85.00%)
Covid-19 mAbs \| Emerging Markets
Product sales
Product Sales				$ 5
Product sales net of reversals	(3)
Actual %, year-on-year				(95.00%)
CER %, year-on-year				(95.00%)
Covid-19 mAbs \| Europe
Product sales
Product Sales	$ 3			$ 7
Actual %, year-on-year	(96.00%)			(95.00%)
CER %, year-on-year	(97.00%)			(95.00%)
Covid-19 mAbs \| Established ROW
Product sales
Product Sales				$ 114
Product sales net of reversals	$ (1)
Actual %, year-on-year				(6.00%)
CER %, year-on-year				6%
Vaxzevria
Product sales
Product Sales				$ 28
Actual %, year-on-year				(98.00%)
CER %, year-on-year				(98.00%)
Vaxzevria \| Emerging Markets
Product sales
Product Sales				$ 18
Actual %, year-on-year				(97.00%)
CER %, year-on-year				(97.00%)
Vaxzevria \| Europe
Product sales
Product Sales				$ 10
Actual %, year-on-year				(96.00%)
CER %, year-on-year				(96.00%)
Beyfortus
Product sales
Product Sales	2			$ 2
Beyfortus \| Europe
Product sales
Product Sales	2			2
Synagis
Product sales
Product Sales	$ 87			$ 284
Actual %, year-on-year	8%			1%
CER %, year-on-year	16%			8%
Synagis \| Emerging Markets
Product sales
Product Sales	$ 49			$ 126
Actual %, year-on-year	16%			17%
CER %, year-on-year	27%			23%
Synagis \| Europe
Product sales
Product Sales	$ 10			$ 92
Actual %, year-on-year	(48.00%)			(13.00%)
CER %, year-on-year	(47.00%)			(9.00%)
Synagis \| Established ROW
Product sales
Product Sales	$ 28			$ 66
Actual %, year-on-year	63%			3%
CER %, year-on-year	75%			15%
FluMist
Product sales
Product Sales				$ 3
FluMist \| Europe
Product sales
Product Sales				3
Total rare diseases
Product sales
Product Sales	$ 1,953			$ 3,819
Actual %, year-on-year	8%			9%
CER %, year-on-year	10%			12%
Total rare diseases \| Emerging Markets
Product sales
Product Sales	$ 150			$ 324
Actual %, year-on-year	65%			57%
CER %, year-on-year	78%			67%
Total rare diseases \| US
Product sales
Product Sales	$ 1,196			$ 2,290
Actual %, year-on-year	12%			10%
Total rare diseases \| Europe
Product sales
Product Sales	$ 381			$ 767
Actual %, year-on-year	2%			5%
CER %, year-on-year	2%			8%
Total rare diseases \| Established ROW
Product sales
Product Sales	$ 226			$ 438
Actual %, year-on-year	(15.00%)			(6.00%)
CER %, year-on-year	(9.00%)			4%
Soliris
Product sales
Product Sales	$ 814			$ 1,648
Actual %, year-on-year	(21.00%)			(18.00%)
CER %, year-on-year	(19.00%)			(16.00%)
Soliris \| Emerging Markets
Product sales
Product Sales	$ 99			$ 214
Actual %, year-on-year	57%			60%
CER %, year-on-year	74%			76%
Soliris \| US
Product sales
Product Sales	$ 445			$ 893
Actual %, year-on-year	(23.00%)			(23.00%)
Soliris \| Europe
Product sales
Product Sales	$ 184			$ 367
Actual %, year-on-year	(15.00%)			(16.00%)
CER %, year-on-year	(15.00%)			(14.00%)
Soliris \| Established ROW
Product sales
Product Sales	$ 86			$ 174
Actual %, year-on-year	(50.00%)			(38.00%)
CER %, year-on-year	(47.00%)			(33.00%)
Ultomiris
Product sales
Product Sales	$ 713			$ 1,364
Actual %, year-on-year	64%			60%
CER %, year-on-year	66%			64%
Ultomiris \| Emerging Markets
Product sales
Product Sales	$ 17			$ 30
CER %, year-on-year				2%
Ultomiris \| US
Product sales
Product Sales	$ 434			$ 815
Actual %, year-on-year	84%			79%
Ultomiris \| Europe
Product sales
Product Sales	$ 152			$ 311
Actual %, year-on-year	26%			38%
CER %, year-on-year	26%			42%
Ultomiris \| Established ROW
Product sales
Product Sales	$ 110			$ 208
Actual %, year-on-year	53%			46%
CER %, year-on-year	64%			62%
Strensiq
Product sales
Product Sales	$ 300			$ 562
Actual %, year-on-year	24%			25%
CER %, year-on-year	25%			26%
Strensiq \| Emerging Markets
Product sales
Product Sales	$ 9			$ 24
Actual %, year-on-year	(1.00%)			33%
CER %, year-on-year	(4.00%)			26%
Strensiq \| US
Product sales
Product Sales	$ 248			$ 453
Actual %, year-on-year	29%			28%
Strensiq \| Europe
Product sales
Product Sales	$ 21			$ 42
Actual %, year-on-year				5%
CER %, year-on-year	(1.00%)			8%
Strensiq \| Established ROW
Product sales
Product Sales	$ 22			$ 43
Actual %, year-on-year	16%			12%
CER %, year-on-year	25%			23%
Koselugo
Product sales
Product Sales	$ 80			$ 159
Actual %, year-on-year	28%			57%
CER %, year-on-year	30%			57%
Koselugo \| Emerging Markets
Product sales
Product Sales	$ 14			$ 38
Actual %, year-on-year	36%
CER %, year-on-year	38%
Koselugo \| US
Product sales
Product Sales	$ 48			$ 89
Actual %, year-on-year	2%			15%
Koselugo \| Europe
Product sales
Product Sales	$ 12			$ 23
Koselugo \| Established ROW
Product sales
Product Sales	6			9
Kanuma
Product sales
Product Sales	$ 46			$ 86
Actual %, year-on-year	28%			16%
CER %, year-on-year	30%			17%
Kanuma \| Emerging Markets
Product sales
Product Sales	$ 11			$ 18
Actual %, year-on-year				95%
CER %, year-on-year				96%
Kanuma \| US
Product sales
Product Sales	$ 21			$ 40
Actual %, year-on-year	5%			4%
Kanuma \| Europe
Product sales
Product Sales	$ 12			$ 24
Actual %, year-on-year	5%			5%
CER %, year-on-year	4%			7%
Kanuma \| Established ROW
Product sales
Product Sales	$ 2			$ 4
Actual %, year-on-year	(4.00%)			12%
CER %, year-on-year	3%			22%
Andexxa
Product sales
Product Sales	$ 45			$ 89
Actual %, year-on-year	23%			28%
CER %, year-on-year	26%			33%
Andexxa \| US
Product sales
Product Sales	$ 16			$ 37
Actual %, year-on-year	(10.00%)			(12.00%)
Andexxa \| Europe
Product sales
Product Sales	$ 15			$ 29
Actual %, year-on-year	70%			64%
CER %, year-on-year	74%			70%
Andexxa \| Established ROW
Product sales
Product Sales	$ 14			$ 23
Actual %, year-on-year	44%
CER %, year-on-year	49%
Total Other medicines
Product sales
Product Sales	$ 301			$ 613
Actual %, year-on-year	(28.00%)			(27.00%)
CER %, year-on-year	(24.00%)			(22.00%)
Total Other medicines \| Emerging Markets
Product sales
Product Sales	$ 185			$ 390
Actual %, year-on-year	(3.00%)			(1.00%)
CER %, year-on-year	4%			6%
Total Other medicines \| US
Product sales
Product Sales	$ 32			$ 68
Actual %, year-on-year	(11.00%)			(9.00%)
Total Other medicines \| Europe
Product sales
Product Sales	$ 26			$ 48
Actual %, year-on-year	(16.00%)			(28.00%)
CER %, year-on-year	(17.00%)			(27.00%)
Total Other medicines \| Established ROW
Product sales
Product Sales	$ 58			$ 107
Actual %, year-on-year	(64.00%)			(65.00%)
CER %, year-on-year	(61.00%)			(61.00%)
Nexium
Product sales
Product Sales	$ 248			$ 492
Actual %, year-on-year	(28.00%)			(27.00%)
CER %, year-on-year	(23.00%)			(22.00%)
Nexium \| Emerging Markets
Product sales
Product Sales	$ 149			$ 305
Actual %, year-on-year	3%			6%
CER %, year-on-year	11%			14%
Nexium \| US
Product sales
Product Sales	$ 30			$ 60
Actual %, year-on-year				(6.00%)
Nexium \| Europe
Product sales
Product Sales	$ 14			$ 25
Actual %, year-on-year	16%			(4.00%)
CER %, year-on-year	15%			(2.00%)
Nexium \| Established ROW
Product sales
Product Sales	$ 55			$ 102
Actual %, year-on-year	(65.00%)			(65.00%)
CER %, year-on-year	(62.00%)			(62.00%)
Other, Others
Product sales
Product Sales	$ 53			$ 121
Actual %, year-on-year	(29.00%)			(28.00%)
CER %, year-on-year	(27.00%)			(25.00%)
Other, Others \| Emerging Markets
Product sales
Product Sales	$ 36			$ 85
Actual %, year-on-year	(22.00%)			(20.00%)
CER %, year-on-year	(18.00%)			(15.00%)
Other, Others \| US
Product sales
Product Sales	$ 2			$ 8
Actual %, year-on-year	(68.00%)			(26.00%)
Other, Others \| Europe
Product sales
Product Sales	$ 12			$ 23
Actual %, year-on-year	(36.00%)			(44.00%)
CER %, year-on-year	(36.00%)			(44.00%)
Other, Others \| Established ROW
Product sales
Product Sales	$ 3			$ 5
Actual %, year-on-year	(28.00%)			(49.00%)
CER %, year-on-year	(31.00%)			(47.00%)

[1] The Q2 2023 and Q2 2022 information in respect of the three months ended 30 June 2023 and 30 June 2022 respectively included in the Interim Financial Statements have not been reviewed by PricewaterhouseCoopers LLP.

Alliance Revenue (Details)

Alliance Revenue (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
Alliance Revenue (Details) - USD ($) $ in Millions	Jun. 30, 2023	[1]	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disclosure of products and services [line items]
Alliance revenue	$ 341		$ 138	$ 627	$ 290
Enhertu
Disclosure of products and services [line items]
Alliance revenue				475	175
Tezspire
Disclosure of products and services [line items]
Alliance revenue				105	16
Vaxzevria: royalties
Disclosure of products and services [line items]
Alliance revenue					60
Other royalty income
Disclosure of products and services [line items]
Alliance revenue				41	34
Other Alliance Revenue
Disclosure of products and services [line items]
Alliance revenue				$ 6	$ 5

[1] The Q2 2023 and Q2 2022 information in respect of the three months ended 30 June 2023 and 30 June 2022 respectively included in the Interim Financial Statements have not been reviewed by PricewaterhouseCoopers LLP.

Collaboration Revenue (Details)

Collaboration Revenue (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
Collaboration Revenue (Details) - USD ($) $ in Millions	Jun. 30, 2023	[1]	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenues
Total collaboration revenue	$ 193		$ 3	$ 220	$ 261
Lynparza, regulatory milestones
Revenues
Total collaboration revenue					175
COVID-19 mAbs: licence fees
Revenues
Total collaboration revenue				180
Farxiga: sales milestones
Revenues
Total collaboration revenue				25
Tralokinumab, sales milestones
Revenues
Total collaboration revenue					70
Other Collaboration Revenue
Revenues
Total collaboration revenue				$ 15	$ 16

[1] The Q2 2023 and Q2 2022 information in respect of the three months ended 30 June 2023 and 30 June 2022 respectively included in the Interim Financial Statements have not been reviewed by PricewaterhouseCoopers LLP.

Other operating income and ex_3

Other operating income and expense (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2023	[1]	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating profit, other operating income and expense
Total other operating income and expense	$ 784		$ 122	$ 1,163	$ 219
Brazikumab licence termination funding
Operating profit, other operating income and expense
Total other operating income and expense				75	69
Divestment of US rights to Plendil
Operating profit, other operating income and expense
Total other operating income and expense					61
Divestment of US rights to Pulmicort Flexhaler
Operating profit, other operating income and expense
Total other operating income and expense				241
Update to the contractual relationships for Beyfortus (nirsevimab)
Operating profit, other operating income and expense
Total other operating income and expense				712
Other
Operating profit, other operating income and expense
Total other operating income and expense				$ 135	$ 89

[1] The Q2 2023 and Q2 2022 information in respect of the three months ended 30 June 2023 and 30 June 2022 respectively included in the Interim Financial Statements have not been reviewed by PricewaterhouseCoopers LLP.